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   Abstract 
Loss of dopamine in Parkinson’s disease is associated with glutamatergic hyperactivity of 
the subthalamic nucleus. Pharmacological and electrical therapies aimed to suppress this 
overactivity favourably alleviate parkinsonian motor symptoms. No study has explored the 
potential of botulinum neurotoxin A in the central nervous system beyond cholinergic 
blockage despite evidence of its ability to inhibit glutamate release. Thus, the present study 
investigated the effect of selective suppression of hyperactive glutamatergic input from the 
subthalamic nucleus to the entopeduncular nucleus by botulinum neurotoxin A in a 
parkinsonian model. Unilateral 6-hydroxydopamine lesioned rodents received 
microinfusions of botulinum neurotoxin A or vehicle into the ipsilateral entopeduncular 
nucleus, and their mobility was assessed using the CatWalk apparatus. Administration of a 
single dose of botulinum neurotoxin A (0.5 ng) significantly improved the rotational 
asymmetry and dynamic gait abnormalities, suggesting a potential use of intracerebral 
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6-OHDA 6 hydroxydopamine 
BG  basal ganglia 
BoNT  botulinum neurotoxin 
BSA  bovine serum albumin 
ChAT  choline acetyltransferase  
CPu  caudate putamen 
DBS  deep brain stimulation 
EPN   entopeduncular nucleus 
GABA  -amino-butyric acid  
GAD67 glutamate decarboxylase 67 kDa 
GFAP  glial fibrillary acidic protein  
GPe  external globus pallidus 
GPi   internal globus pallidus 
HC  carboxy-terminal of the heavy chain 
HN   amino-terminal of the heavy chain 
IP  intraperitoneal 
L chain  light chain 
L-DOPA L-3,4-dihydroxyphenylalanine 
LF  left front 
LH  left hind 
LRRK2 leucine-rich repeat kinase 2 
MFB  medial forebrain bundle 
MLR  mesencephalic locomotor region 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MSN  medium spiny neuron 
PB  phosphate buffer 
PBS  phosphate buffered saline 
PD  Parkinson’s disease  
PPN  pedunculopontine nucleus  




RH  right hind 
ROS  reactive oxidative species 
SC  subcutaneous  
SNAP-25 synaptosomal-associated protein 25 
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein 
SNpc  substantia nigra pars compacta 
SNpr  substantia nigra pars reticulata  
STN  subthalamic nucleus 
SV2  synaptic vesicle protein 2 
TH  tyrosine hydroxylase  
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Chapter 1  
1 Introduction  
Parkinson’s disease is a common neurodegenerative disorder, which is associated with a 
spectrum of motor and cognitive symptoms unique to each individual. Despite tremendous 
breakthroughs in research to understand the complexity of this disease, many key questions 
remain unanswered. The exact cause of Parkinson’s disease is still unknown and although 
various treatments exist for symptomatic relief, there is currently no cure.  
This chapter aims to provide a general overview of Parkinson’s disease, outline the neural 
circuitry involved in this disorder, highlight common parkinsonian animal models used in 
research, and introduce the potential of botulinum neurotoxin as a novel therapeutic.  
 
1.1 Parkinson’s Disease  
1.1.1 Overview 
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by the 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). This complex 
disorder was first medically described by its prominent motor abnormalities by James 
Parkinson in 1817 (Parkinson, 2002). Over 50 years later, Jean-Martin Charcot further 
described and refined the cardinal symptoms of PD (Goetz, 2011). The chief parkinsonian 
motor symptoms are bradykinesia, resting tremor, rigidity, and postural instability. 
Currently, PD is the second most common neurodegenerative disorder after Alzheimer’s 
disease. It is estimated that PD affects over 7 million individuals globally and about 1% of 
the population over 60 years of age (De Lau et al., 2006). Furthermore, it is expected that 
the prevalence of PD will more than double by 2030 (Dorsey et al., 2007). In Canada, PD 
affects over 100 000 people and 85% of those diagnosed are over 65 years old (Parkinson 
Society Canada, 2003). Due to the chronic and progressive nature of the disease, patients 
often experience gradual complications and a reduced quality of life. This leads to an 
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escalating economic burden on patients, society and the healthcare system (Whetten-
Goldstein, 1997). Accordingly, it is estimated that the total annual cost of PD in North 
America will exceed $50 billion by 2040 (Findley, 2007). With an aging population and 
growing economic burden, there is an ongoing need to research the mechanisms underlying 
the pathogenesis of PD and to identify novel management and treatment options. 
 
1.1.2 Pathology 
The main pathological hallmark of PD is the death of neuromelanin-pigmented 
dopaminergic neurons in the substantia nigra, with predominant loss in the lateroventral 
component of the pars compacta. At the onset of motor symptoms, it is estimated that there 
is a 68% dopaminergic loss in the lateroventral region, a 48% neuronal loss in the whole 
nigra and an 80% loss of axon terminals at the striatum (Fearnley & Lee, 1991; Bernheimer 
et al., 1973). This neuronal death is accompanied by the appearance of intraneuronal 
inclusions called Lewy bodies in distinct areas of the brain. Lewy bodies are abnormal 
proteinaceous inclusions containing aggregates of α-synuclein and other neurofilamentous 
proteins (Spillantini et al., 1997; Baba et al., 1998). The distribution of these Lewy bodies 
is used to classify the degree of sporadic PD pathology (Braak, 2003; Braak, 2006). Based 
on Braak staging, the earliest pathological changes occur in the dorsal motor nucleus of the 
vagus and olfactory bulb (Stages 1 and 2). As the disease advances, pathological changes 
are observed in the substantia nigra, areas of the midbrain and basal forebrain (Stages 3 
and 4) until finally, the neocortex is affected (Stages 5 and 6). This classification helps to 
elucidate the progression of PD symptoms from early olfactory dysfunction (Stages 1 and 
2) to motor deficits (Stages 3 and 4) and ultimately, to cognitive impairments in advanced 
stages (Stages 5 and 6). The formation of Lewy bodies is one of the major proposed theories 
underlying neuronal death in idiopathic PD, yet the exact mechanistic cascade is unknown 
(Gibb & Lees, 1988). Other leading pathological factors include mitochondrial 
dysfunction, increased oxidative stress, disruption of autophagy, and activation of 
microglia (Lin & Beal, 2006; Narendra, Tanaka, Suen, & Youle, 2008; Glass, Saijo, 




Although the cause of PD is not yet known, both genetic and environmental factors have 
been associated to an increased risk of disease development. While majority of cases of PD 
are idiopathic, approximately 5-15% of cases are associated to familial mutations in 
specific autosomal genes (Lesage & Brice, 2008). Amongst the many PD-related genes 
that have been identified, the most extensively studied genes are SNCA (codes for α-
synuclein) and leucine-rich repeat kinase 2 (LRRK2; codes for dardarin), which are 
transmitted in an autosomal-dominant inheritance pattern (Polymeropoulos et al., 1997; 
Simon-Sanchez et al., 2009; Lesage & Brice, 2008). While the discovery of PD-linked 
genes has tremendously furthered the field of PD research, the clear majority of PD cases 
cannot be solely attributed to genetic factors. This suggests a multifactorial aetiology, 
which includes an environment contribution as well.    
There are numerous environmental risk factors that have been thought to contribute to the 
aforementioned pathological mechanisms underlying PD (Goldman, 2014). Of the many 
potential environmental factors, in vitro, animal and epidemiological studies most strongly 
support a link with exposure to pesticides and heavy metals. Implicated pesticides include 
rotenone, paraquat and organochlorine compounds (Cannon et al., 2009; McCormack et 
al., 2002; Tanner et al., 2011; Elbaz et al., 2009). Dysregulated iron homeostasis and 
augmented exposure to manganese are also implicated in PD aetiology (Dexter et al., 1989; 
Coon et al., 1989, Aschner et al., 2009). Other environmental factors, such as head injuries 
and pollution may also contribute to an increased risk of PD (Goldman, 2014).  
Although the role of both genetic and environmental factors to development of PD is not 
fully understood, it is evident that their contribution is linked to the mechanistic pathways 
underlying PD pathogenesis.   
 
1.1.4 Symptoms 
Although PD is generally thought of as a disorder of movement, it is associated with both 
motor and non-motor symptoms. The cardinal motor symptoms of PD are bradykinesia, 
resting tremor, rigidity, and postural instability (Jankovic, 2008). 
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Bradykinesia is characterized as the slowness of voluntary movement due to a progressive 
reduction in speed and amplitude of continuous activity (Berardelli, Rothwell, Thompson, 
& Hallett, 2001). Classically, bradykinesia is the most characteristic feature of PD and a 
hallmark of basal ganglia disorders. It encompasses dysfunction in all aspects of motor 
control, from planning to initiation to execution of movement (Cooper, Sagar, Tidswell, & 
Jordan, 1994). Initial indicators include slowness in performing daily tasks that require fine 
motor control and slower reaction times. Other manifestations present as impaired 
swallowing, dysarthria, hypomimia, and reduced arm swing while walking (Jankovic, 
2008). 
Tremor is the most common and apparent symptom of PD (Jankovic, 2008). It refers to the 
alternating contraction and relaxation of agonist and antagonist muscles. Characteristically, 
tremor occurs at a frequency between 4 to 6 Hz during rest and appears in a unilateral 
manner at a distal part of the limb. The occurrence of rest tremor is variable amongst PD 
patients with approximately 70% of patients reporting tremor at disease onset and at least 
75% of patients affected by tremor at some point in disease (Hughes, Daniel, Blankson, & 
Lees, 1993).  
Rigidity refers to an increased stiffness and resistance to limb movement due to the 
excessive and sustained contraction of muscles (Jankovic, 2008). It may present in a 
uniform or ratchet-like manner and most often occurs asymmetrically. Increased muscle 
tone at the neck and trunk leads to axial rigidity, which often results in postural deformities 
that appear more frequently at early stages of PD (Ashour & Jankovic, 2006). As the 
disease progresses, rigidity typically spreads distally to the face and extremities, ultimately 
resulting in a reduction in the ability to move.  
Postural instability usually manifests at late stages of PD due to the loss of postural reflexes 
and impaired balance (Jankovic, 2008). This symptom along with freezing of gait 
contributes significantly to an increased frequency of falls (Williams, Watt, & Lees, 2006).   
In addition to these four cardinal motor symptoms of PD, other motor impairments include 
gait abnormalities, bulbar dysfunction, and neuro-ophthalmological disturbances (Bloem, 
Harusdorff, Visser, & Giladi, 2004; Hunker, Abbs, & Barlow, 1982; Biousse, Skibell, 
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Watts, Loupe, Drews-Botsch, & Newman, 2004). Gait dysfunction in PD will be discussed 
in detail in Chapter 1.4.  
Non-motor symptoms of PD are also common and can even present prior to the 
aforementioned motor symptoms (Poewe, 2008). These include autonomic dysfunction, 
neuropsychiatric disturbances (changes in mood, cognition and behaviour), and sensory 
and sleep abnormalities. 
 
1.1.5 Treatment 
As there is no cure for PD, current treatment strategies focus on providing symptomatic 
relief by medications and/or surgery. Most interventions only treat certain symptoms of the 
disease but have not been shown to slow the rate of progression of PD nor have been 
confirmed as displaying neuroprotective, neurorescuing or neurorestorative effects 
(National Collaborating Centre for Chronic Conditions, 2006). Typically, medications act 
by either replenishing dopamine levels in the brain or mimicking the effects of dopamine. 
The gold standard symptomatic therapy for PD is L-3,4-dihydroxyphenylalanine (levodopa 
or L-DOPA), a dopamine precursor (Parkinson Study Group, 2004). After crossing the 
blood-brain barrier, levodopa is readily converted into dopamine by aromatic L-amino acid 
decarboxylase (Rahman, Toshiharu, & Takeshi, 1981). Typically, levodopa is given with 
a peripheral dopamine decarboxylase inhibitor to block peripheral conversion of levodopa 
to dopamine. At earlier stages of disease, treatment with levodopa improves many motor 
symptoms of PD, including bradykinesia, rigidity and tremor, but there is a decrease in 
effectiveness as the disease progresses (Parkinson Study Group, 2004). Additionally, long-
term levodopa therapy may lead to the development of complications, such as dyskinesias 
and motor fluctuations (Rascol et al., 2000, Marsden & Parkes, 1977).  
When complications arise that cannot be satisfactorily controlled by medical therapy, 
surgical interventions, such as lesioning of affected areas or deep brain stimulation (DBS) 
are available. Although creation of lesions at the internal globus pallidus (GPi) or 
subthalamic nucleus (STN) provides some benefits to patients, it includes the risk of 
inducing neurological deficits, particularly with bilateral procedures (Hariz, 2000). 
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Alternatively, DBS of these same brain targets mirrors the effect of a lesion without 
deliberately causing damage to the brain (Benabid, Pollak, Louveau, Henry & De 
Rougemont, 1987). DBS is associated to an improvement in motor scores for patients with 
advanced PD while reducing dyskinesia and motor fluctuations (Deep-Brain Stimulation 
for Parkinson's Disease Study Group, 2001). However, the mechanism of action of DBS 
remains elusive with many proposed mechanisms. Furthermore, other caveats of DBS 
include its unavailability to people with cognitive or psychiatric problems and its 
inconclusive effect to improve speech, balance and aspects of gait (Bronstein et al., 2011).   
Although medical and surgical interventions are available for the treatment of PD, they are 
each associated with their own advantages and disadvantages. There is a clear unmet need 
for exploring novel interventions that could be applied to many patients, offer novel 
neuromodulatory effects with an already understood mechanism and even target multiple 
affected sites within the brain.  
 
1.2 Neural Circuitry Involved in Parkinson’s Disease 
1.2.1 Overview of Basal Ganglia Circuitry  
The proper execution of voluntary movement requires the correct integration of sensory to 
motor information in the brain. This is accomplished by an intricate neural network, which 
includes the cerebral cortex, the motor thalamus and the basal ganglia (BG) nuclei (Albin 
Young, & Penney, 1989; Blandini, Nappi, Tassorelli, & Martignoni, 2000; DeLong & 
Whichmann, 2007). Overall, the BG play a crucial role at the centre of this looped circuit 
by modulating afferent information from the cortex to produce an efferent signal that 
returns through the thalamus back to the cortex (Obeso et al., 2008). A schematic overview 
of the BG circuitry in a normal state is presented in Figure 1 A.  
The BG are located at the base of the telencephalon and comprise of multiple 
interconnected nuclei: the striatum (dorsal: caudate nucleus and putamen; ventral: nucleus 
accumbens and olfactory tubercle), the globus pallidus (internal [GPi] and external [GPe]), 
7 
 
the substantia nigra (pars compacta [SNpc] and pars reticulata [SNpr]) and the subthalamic 
nucleus (STN) (Blandini, 2000).  
Of these structures, the striatum is the main input nucleus of the BG. The clear majority 
(approximately 95%) of neurons in the striatum are characterized as medium spiny neurons 
(MSNs) that release -amino-butyric acid (GABA) as a neurotransmitter (Kemp & Powell, 
1971). These MSNs receive predominately glutamatergic projections from all cortical 
areas and then send projections to their main targets, the SNpr, GPi and GPe (Parent & 
Hazrati, 1995). In the rat, it is estimated that approximately 5000 glutamatergic inputs 
converge onto a single striatal MSN and then, 100 MSNs project onto each pallidal neuron 
(Obeso et al., 2008). Thus, this arrangement is in need of a precise filtering mechanism to 
select incoming and outgoing signals required to perform specific movements. This 
filtering activity is principally facilitated by dopamine (Bamford et al., 2004; Obeso et al., 
2008). Accordingly, the striatum is also innervated by dopaminergic inputs originating in 
the SNpc (Beckstead, Domesick, & Nauta, 1993). Striatal neurons express D1 and/or D2 
receptors, with majority of D1 receptors expressed by neurons projecting to the GPi and 
SNpr, while D2 receptors are expressed by neurons projecting to the GPe (Gerfen et al., 
1995; Yung et al., 1995). Moreover, the incoming cortical projections to MSNs that express 
D1 receptors are relatively distinct from those that project to MSNs expressing D2 
receptors, from cortical layer III versus layer V respectively (Lei, Jiao, Del Mar, & Reiner, 
2004). It is generally accepted that this functional segregation of the inputs and outputs of 
the striatum has formed the basis for the direct and indirect pathway model of BG 
functional organization (Blandini et al., 2000).  
In the direct pathway, dopamine exerts an excitatory role on striatal GABAergic neurons, 
which express dynorphin, substance P and D1 receptors. These D1 expressing striatal 
neurons project inhibitory information directly to the GPi and SNpr. The entopeduncular 
nucleus (EPN), which is the rat’s equivalent to the human GPi, shares many histological 
and functional properties to the SNpr. Together, the GPi/EPN and SNpr are considered the 
main output nuclei of the BG (Blandini et al., 2000). They are populated by GABAergic 
neurons and send their inhibitory projections primarily to the ventral anterior and ventral 
lateral thalamic nuclei, which in turn project to the motor cortex (Parent & Hazrati, 1995).  
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In the indirect pathway, dopamine exerts an inhibitory role on striatal GABAergic neurons, 
containing enkephalin as a co-transmitter and expressing D2 receptors. These D2 
expressing striatal neurons send their information indirectly to the output nuclei through a 
more complicated route involving the GPe and STN (Blandini et al., 2000). The GPe 
receives major afferent projections from the striatum (inhibitory GABAergic fibers) and 
the STN (excitatory glutamatergic fibers) (Parent & Hazrati, 1995). The inhibitory GPe 
then projects to many structures within the BG circuitry, including the STN, GPi/EPN, 
SNpr and SNpc (Parent & Hazrati, 1995). The STN is the only glutamatergic nucleus of 
the BG and sends its excitatory information primarily to the BG output nuclei, the GPi/EPN 
and SNpr, as well as reciprocally to the GPe and pedunculopontine nucleus (PPN) (Kita & 
Kitai, 1987). In addition to receiving information through the indirect pathway, the STN is 
also innervated by the motor cortex, thalamus and PPN (Canteras, Shammah-Lagnado, 
Silva, & Ricardo, 1990).  
The functional consequence of this complex organization is that stimulation of the direct 
versus the indirect pathway results in opposite effects in the net outcome of the BG circuitry 
(Blandini et al., 2000). Activation of striatal GABAergic MSNs of the direct pathway leads 
to inhibition of GABAergic neurons of the output nuclei. This results in disinhibition or 
facilitation of the thalamus, due to the lack of inhibitory control by those output nuclei. 
Consequently, the thalamus sends its projections to the motor cortex to facilitate 
movement. On the contrary, activation of striatal GABAergic MSNs of the indirect 
pathway leads to inhibition of the GABAergic GPe and subsequent disinhibition of the 
glutamatergic STN. This results in increased excitatory outflow from the STN to the output 
nuclei, which ultimately enhances their inhibitory activity. Consequently, this contributes 
to greater inhibitory outflow to the thalamocortical motor centers to inhibit movement. 
As mentioned before, dopamine serves as a crucial modulator at the centre of this complex 
network. Dopamine acts on D1 receptors to enhance the role of the direct pathway and on 
D2 receptors to inhibit the role of the indirect pathway. Therefore, in simplistic terms, the 
net effect of dopamine on the BG circuitry in a normal individual is to facilitate movement 
(Blandini et al., 2000). 
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1.2.2 Changes in Basal Ganglia Circuitry in Parkinson’s Disease 
PD is characterized by the degeneration of dopaminergic neurons in the SNpc, which 
triggers a cascade of changes in BG circuitry (Albin et al., 1989). Present concepts of BG 
circuitry propose that the loss of dopaminergic denervation of the striatum in PD results in 
decreased excitation through the direct pathway and increased inhibition through the 
indirect pathway (Albin et al., 1989; Blandini et al., 2000). Together, this imbalance of 
these pathways contributes to enhanced inhibitory activity of the output nuclei. As a result, 
there is greater inhibitory outflow to the thalamocortical motor centers, which are then 
unable to facilitate movement. These alterations in BG circuitry underlie an array of PD 
motor symptoms such as tremor, rigidity, and bradykinesia (Obeso et al., 2008). An 
overview of changes in BG circuitry in PD is presented in Figure 1 B. 
In more detail, the loss of dopamine acting on D1 receptors causes a decrease in activation 
of GABAergic MSNs of the direct pathway. This results in less inhibition on the GPi/EPN 
and SNpr, which in turn send inhibitory projections to the thalamus to inhibit movement. 
On the contrary, the loss of dopamine acting on D2 receptors causes an increase in 
activation of GABAergic MSNs of the indirect pathway. This results in more inhibition of 
the GPe, and subsequent disinhibition of the STN. Hence in PD, the STN is considered 
overactive due to its increased excitatory outflow to the output nuclei, the GPi/EPN and 
SNpr. This enhanced activation of these output nuclei results in greater inhibition to the 
ventral anterior and ventral lateral thalamic nuclei, which in turn fail to stimulate the motor 
cortex. 
Thus, amongst this complicated network, it is evident that the STN, which is the only 
glutamatergic BG nuclei, plays a key role in the facilitation or inhibition of movement. It 
is well accepted that the loss of dopamine in PD causes the STN to become overactive, but 
this overactivity is not fully understood (Rodriguez, Obeso, & Olanow, 1998). As a result, 
there has been much focus on understanding the role of the STN in PD. Moreover, the STN 
has become a key target site for implementing interventions to treat and manage symptoms 
of PD, such as DBS. There is strong evidence that suggests that novel pharmacological or 
surgical therapies that are able to reduce STN neuronal overactivity or impair glutamate 
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transmission at its target structures, such as the GPi/EPN may be highly promising in the 
treatment of PD.    
 
Figure 1 – BG circuitry in normal and parkinsonian states  
Schematic diagram of the direct and indirect pathways of the BG circuitry in normal (A) 
and parkinsonian states (B). Black arrows represent excitatory projections and grey arrows 
represent inhibitory projections. The thickness of the arrows indicates changes in activity 
of specific connections in PD.  
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1.3 Animal Models of Parkinson’s Disease 
1.3.1  Common Animal Models 
Over the past few decades, significant strides in clinical research and post-mortem studies 
medicine have contributed to a better understanding of PD. However, many important 
questions regarding the etiology, pathology and molecular biology of PD remain 
unanswered. While cell and tissue models are helpful in investigating the underlying 
molecular pathways, animal models offer deeper insight to understand the pathogenesis of 
PD and to test the potential of novel neuroprotective, neurorestorative or neuromodulatory 
interventions (Blesa & Przedborski, 2014). Classically, these animal models are grouped 
into two main categories: genetic or toxic models (Blesa, Phani, Jackson-Lewis, & 
Przedborski, 2012). Even though nearly all the hallmarks of PD can be mimicked by 
different experimental models, none of the currently available animal models fully 
phenocopy the human condition, as they lack some specific neuropathological and/or 
behavioural feature (Blesa & Przedborski, 2014). Thus, each model has certain strengths 
and weaknesses, which all must be considered when selecting the appropriate and optimal 
model for the question being asked.  
The development of genetic animal models of PD has been more recently invigorated due 
to the identification of several PD-linked genes. Although the vast majority of PD cases 
are idiopathic, the use of overexpressed or knocked-out genes linked to PD in animals may 
help to reveal the cascade of molecular events underlying the death of dopaminergic 
neurons. Transgenic mice with mutations in α-synuclein demonstrate some alterations in 
behaviour, but no consistent loss of dopaminergic neurons in the substantia nigra (Oaks, 
Frankfurt, Finkelstein, & Sidhu, 2013; van der Putten et al., 2000). Similarly, LRRK2 
knock-out mice failed to reproduce the neuropathological features of PD and LRRK2 
mutations knock-in mice did not demonstrate considerable striatal dopamine loss or 
sustained motor deficits (Hinkle et al., 2012; Tong et al., 2009; Ramonet et al., 2011). Other 
genetic models of PD-related genes, such as PINK1, Parkin and DJ-1 all failed to exhibit 
obvious behavioural changes or reduce nigrostriatal dopamine levels (Gispert et al., 2009; 
Itier et al., 2003; Goldberg et al., 2005). Thus, although transgenic or knock-out models 
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offer insight in evaluating the role of genetics in PD, they are insufficient in reproducing 
the neuronal degeneration associated with PD.  
Neurotoxic models involve the use of compounds that can produce both reversible and 
irreversible effects (Blesa & Przedborski, 2014). Similar to genetic models, these toxin-
based animal models each offer their own advantages and disadvantages. Some of the key 
benefits to neurotoxic models over genetic models are their ability to replicate the 
degeneration of the nigrostriatal pathway and to display motor abnormalities (Blesa et al., 
2012). However, most of the neurotoxic models lack the characteristic PD proteinaceous 
inclusions called Lewy bodies (Forno, DeLanney, Irwin, & Langston, 1992). Of the toxin-
based models, the most commonly used are the 6-hydroxydopamine (6-OHDA) rat model 
and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model (Schober, 
2004). MPTP is a lipophilic drug that can rapidly cross the blood-brain barrier and thus, it 
can be administered systemically, which makes it very desirable to researchers (Jackson-
Lewis & Przedborski, 2007). After entering astrocytes of the brain, MPTP is activated to 
MPP+ by the enzyme monoamine oxidase-B (Heikkila, Manzino, Cabbat, & Duvoisin, 
1984). MPP+ is then released from the glial cells and selectively picked up by 
dopaminergic neurons by the vesicular monoamine transporter 2 (Javitch, D'Amato, 
Strittmatter, & Snyder, 1985). In the neurons, MPP+ inhibits complex 1 of the 
mitochondrial electron transport chain to reduce ATP production and increase reactive 
oxidative species (ROS) release, which leads to the death of the neurons (Tipton & Singer, 
1993). Consequently, administration of MPTP is able to reproduce bilateral 
neuroanatomical and behavioural effects similar to that of the human PD condition 
(Langston, Langston, & Irwin, 1983; Bankiewicz, 1986). Despite being quite effective at 
mimicking the nigrostriatal loss of dopamine in primates, rats are much less susceptible to 
the adverse effects of MPTP (Chiueh et al., 1984).  For that reason, the 6-OHDA model is 
the most frequently used and best-studied rodent model of PD. Due to its ability to 
reproduce both behavioural and neurodegenerative effects, the 6-OHDA model of PD is 
the chosen parkinsonian animal model that will be used to conduct this research project. 




In addition to these commonly used neurotoxic models, there are pesticide and/or herbicide 
based PD animal models which utilize compounds such as paraquat and rotenone. The 
mechanism of paraquat is very similar to the ability of MPTP to deplete dopamine, but 
administration of paraquat can also induce significant increase of α-synuclein in 
dopaminergic neurons of the substantia nigra (Brooks, Chadwick, Gelbard, Cory-Slechta, 
& Federoff, 1999; Manning-Bog et al., 2002). However, it fails to demonstrate clear motor 
deficits in rodents, which is why it was not chosen for this study. Administration of 
rotenone in rats also leads to the presence of α-synuclein aggregation and mild behavioural 
changes (Betarbet et al., 2000; Cannon et al., 2009). However, the ability of rotenone to 
deplete dopamine remains uncertain and there is a very high rate of mortality associated to 
this model (Wu & Johnson, 2011; Ferrante, Schulz, Kowall, & Beal, 1997; Sherer, Kim, 
Betarbet, & Greenamyre, 2003).  
Overall, based on the benefits and drawbacks of all the main neurotoxic animal models, 
the 6-OHDA model of PD is the best-suited system to study behavioural changes in rodents 
for this study.  
 
1.3.2  Overview of 6-OHDA 
6-OHDA was first isolated over 50 years ago, and shortly after, its toxic effects on selective 
dopaminergic and noradrenergic terminals were demonstrated (Senoh & Witkop, 1959; 
Porter, Totaro, & Stone, 1963). 6-OHDA is a hydroxylated analogue of dopamine and it 
utilizes this similarity to exert its neurotoxic effects (Kostrzewa & Jacobowitz, 1974). As 
6-OHDA does not cross the blood-brain barrier, it cannot be administered systemically 
when producing the PD model. Rather, it is injected directly into the brain by stereotaxic 
surgery (Ungerstedt, 1968). At the target brain region, 6-OHDA exploits the dopamine and 
noradrenaline reuptake transporters to enter the neurons where it can exert its neurotoxic 
effects (Storch, Ludolph, & Schwarz, 2004). In order to selectively destroy dopaminergic 
neurons and prevent uptake by noradrenergic terminals, a noradrenaline reuptake 
transporter blocker, such as desipramine, is often administered in conjunction with 6-
OHDA when creating a PD model (Torres & Dunnett, 2012). 
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After entering a neuron, principally through the dopamine active transporter, 6-OHDA 
mediates its neurotoxic effects by generating oxidative stress and triggering mitochondrial 
dysfunction (Blum et al., 2001). Excessive formation of hydrogen peroxide, hydroxyl 
radicals and superoxide radicals occur via deamination of 6-OHDA by monoamine oxidase 
and/or auto-oxidation (Breese & Traylor, 1971; Heikkila & Cohen, 1972). Consequently, 
the build of oxidative stress reduces antioxidative capabilities of the neurons, exhausts 
phospholipids and impairs regulation of redox potentials (Kumar, Agarwal, & Seth, 1995; 
Shiraga, Pfeiffer, & Ebadi, 1993). 6-OHDA-generated ROS also leads to DNA damage 
and cytoskeleton disorganization (Bruchelt, Schraufstatter, Niethammer, & Cochrane; 
Davison, Legault, & Steele, 1986). Moreover, 6-OHDA targets complex I and IV of the 
mitochondrial electron chain in order to impair mitochondrial function (Glinka & Youdim, 
1995). The combined effects of mitochondrial dysfunction and excessive production of 
oxidative stress impairs the neurons targeted by 6-OHDA from exerting their normal 
physiological functions and consequently triggers their death. 
 
1.3.3  6-OHDA Lesion of the MFB  
As previously mentioned, lesioning of the rat nigrostriatal dopaminergic system with 6-
OHDA is the most commonly used animal model of PD (Torres & Dunnett, 2012). In 
experimental models of PD, 6-OHDA is preferentially injected into the striatum, the 
substantia nigra or the ascending medial forebrain bundle (MFB). The neurotoxic 
consequences of 6-OHDA at these different sites all vary slightly from one another in terms 
of behavioural effects and neuroanatomic depletion of dopamine. 
The MFB is a collection of ascending and descending fibers that connect the medial and 
basal forebrain structures with the midbrain and hypothalamus (Shiosaka et al., 1980). 
Amongst the numerous fibers, the MFB consists of axons of dopaminergic neurons of the 
nigrostriatal pathway (A9 cells) projecting from the SNpc to the caudate putamen (CPu), 
and of the mesolimbic pathway (A10 cells) projecting from the ventral tegmental area to 
the nucleus accumbens (Deumens, Blokland, & Prickaerts, 2002). Direct injection of 6-
OHDA into the MFB unilaterally causes a near complete destruction of A9 and A10 cell 
groups (Perese, Ulman, Viola, Ewing, & Bankiewicz, 1989). Bilateral MFB lesions results 
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in animals suffering from severe aphagia and adipsia, whereas unilaterally lesioned rodents 
are capable of normal eating and drinking (Zigmond & Stricker, 1973). Thus, the unilateral 
6-OHDA model was preferred and used in this research project.  
Unilateral injection of 6-OHDA into the MFB produces a well-established syndrome 
involving: (1) near total depletion of dopamine in the CPu ipsilateral to the lesion, (2) 
denervation supersensitivity of dopamine receptors in the CPu ipsilateral to the lesion, and 
(3) a characteristic rotational behaviour in response to amphetamine and apomorphine 
(Perese et al., 1989; Deumens et al., 2002). These hemiparkinsonian rats demonstrate 
various changes in motor behaviour, particularly in an asymmetric manner. After unilateral 
lesioning of the MFB, rats initially display a preferential turning behaviour toward the side 
of the lesion (Deumens et al., 2002). When drugs that act on the dopaminergic system are 
administered, such as amphetamine and apomorphine, hemiparkinsonian rats display 
further active rotational behaviour (Ungerstedt, 1968). This drug-induced rotational 
phenotype is due to an imbalance in dopamine activity between the lesioned and non-
lesioned striata. With this imbalance in dopamine, animals tend to rotate away from the 
side of greater activity (Ungerstedt, 1971). When hemiparkinsonian rats are challenged 
with amphetamine, they display ipsilateral rotations towards the lesioned side. As a 
dopamine releasing agent, amphetamine stimulates the release of dopamine and blocks its 
reuptake. This results in greater dopamine activity on the side of the intact nigrostriatal 
projection, and thus animals rotate toward the lesioned side. On the other hand, when 
hemiparkinsonian rats are challenged with apomorphine, they display contralateral 
rotations away from the lesioned side. This is due to the phenomenon known as 
supersensitivity, in which there is an upregulation of D1 and D2 postsynaptic receptors in 
the denervated striatum. With this supersensitivity of dopamine receptors, there is greater 
dopamine activity on the side of the lesioned nigrostriatal projection, and thus animals 
rotate away from the lesioned side (Ungerstedt, 1971; Deumens et al., 2002). Only rats 
who demonstrate extensive lesions (>90% reduction in dopaminergic fiber density in the 
CPu) will demonstrate contralateral rotational behaviour following administration of 
apomorphine (Hudson et al., 1993). However, rats with moderate lesioning (75-90% 
reduction in dopaminergic fiber density in the CPu) will demonstrate ipsilateral rotational 
behaviour following administration of amphetamine but no significant circling behaviour 
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in the presence of apomorphine. Thus, apomorphine is better than amphetamine to predict 
the extent of CPu lesioning following 6-OHDA injection into the MFB (Hudson et al., 
1993; Deumens et al., 2002). Although it varies from study to study, there is a general 
consensus that a minimum of 6 or 7 net contralateral rotations per minute is the standard 
for a successful complete 6-OHDA lesion, which corresponds to approximately 95-99.8% 
depletion of dopamine content in the CPu and 85% depletion in the SNpc (Perese et al., 
1989; Hudson et al., 1993; Deumens et al., 2002, Yuan, Sarre, Ebinger, & Michotte, 2005; 
Torres & Dunnett, 2012).   
In addition to this characteristic rotational phenotype, many other changes in behaviour 
have been demonstrated in this hemiparkinsonian model. 6-OHDA lesioned animals at the 
MFB display clear motor coordination deficits, as measured by the rotarod (Monville, 
Torres, & Dunnett, 2006; Carvalho et al., 2013). Following 6-OHDA lesioning of the MFB, 
animals spent a significantly much shorter time balancing on the rotating rod and were 
more prone to falls, as compared to control animals. Moreover, assessment of exploratory 
and locomotor activity by the open field test, in which rats are allowed to freely roam, 
demonstrated that 6-OHDA lesioned rats display significantly lower motor activity than 
control animals (Carvalho et al., 2013). Following 6-OHDA lesioning, both the total 
distance traversed and the number of ambulatory episodes significantly reduced by a factor 
of four, as compared to controls. Furthermore, 6-OHDA lesioned rats spent significantly 
more time hanging to a wire during the grip strength test (Ma et al., 2014). This reflects an 
increase in muscular tension and indicates that 6-OHDA lesioned rats develop greater limb 
rigidity. In addition, 6-OHDA lesioned animals develop anhedonic behaviour, a main 
feature of depressive-like behaviour. This was demonstrated by a significant reduction in 
preference for sucrose in the sucrose preference test (Carvalho et al., 2013). However, 6-
OHDA lesioned animals do not demonstrate significant differences in terms of time spent 
on the open arms versus closed arms of an elevated plus maze, which is used to assess 
anxiety-like behaviour (Carvalho et al., 2013). Finally, the effect of 6-OHDA lesions on 
cognitive performance remains controversial. A study by Ma et al. (2014) reported that 6-
OHDA lesioned rats demonstrate a significant increase in latency in locating the platform 
during spatial learning trials of the Moris water maze task. On the other hand, a behavioural 
characterization study by Carvalho et al. (2013) described that both reference and working 
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memory performance were not affected by unilateral lesioning of the MFB as measured by 
Morris water maze test (Carvalho et al., 2013). In brief, 6-OHDA lesioned rodents 
demonstrate clear motor deficits, which are demonstrated by an array of spontaneous and 
forced motor tests. However, the effects of MFB lesioning on cognition appear to be less 
clear. Also, it is important to note that specific changes in gait are also observed in 
unilateral 6-OHDA lesioned rats. These features will be discussed in further detail in 
Chapter 1.4.3. 
In conclusion, the 6-OHDA rat model of PD arguably best mimics the human disease at 
advanced stages in terms of neurochemical and behavioural features. Although it has a few 
drawbacks, including being limited to unilateral injections, it remains well suited to test 
preclinical PD therapeutics and changes in specific motor parameters. Thus, unilateral 
lesioning of the MFB with 6-OHDA was the chosen hemiparkinsonian animal model used 
to conduct this research project.  
 
1.4 Gait Dysfunction in Parkinson’s Disease 
1.4.1  Overview 
The act of walking with an automatic and rhythmic gait is a seemingly simple task. 
However, in fact, it involves a complex integration of cortical, subcortical, brainstem and 
spinal cord neural networks to process external sensory information and generate this 
automatic and rhythmic pattern of movement (Nutt, Marsden, & Thompson, 1993). In PD, 
this rhythmic sequence is lost and gait disturbances present as short, shuffling steps with 
freezing episodes, which frequently result in falls that are severely debilitating (Williams 
et al., 2006; Lewis & Marker, 2009).  
Classically, gait is defined as the pattern of leg movements used to complete a stride. A 
stride is the period spanning from the placement of one foot to the ground to when that 
same foot is placed on the ground again. Each stride comprises of a phase of stance, during 
which the foot is in contact with the ground and a phase of swing, during which the foot is 
not in contact with the ground. Affected gait in PD characteristically includes reduced 
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walking velocity (slowness), shorter step length, shorter stride length, increased double 
support time and reduced arm swing (Sofuwa et al., 2005). However, in current literature, 
the appropriate selection of gait parameters remains inconsistent and the conclusions that 
can be drawn from each gait parameter to understand the neurocircuitry dysfunction 
involved in gait and PD is unclear. Many studies have attempted to further elucidate the 
changes in specific gait parameters seen in PD and study their potential improvements 
following treatment, such as levodopa and DBS (Blin, Ferrandez, Pailhous, & Serratrice, 
1991; Verghese, Holtzer, Lipton, & Wang, 2009; Hollman, McDade, & Petersen, 2011).   
A study by Lord, Galna, & Rochester (2013) examined different features of gait, including 
pace, rhythm and variability, in order to associate specific gait parameters to each feature 
and understand their changes in pathological conditions. Pace refers to the speed of walking 
and is primarily linked to the gait parameters of step velocity and step length (Lord et al., 
2013). These kinematic parameters tend to be L-DOPA sensitive and improve following 
treatment (Blin et al., 1991). On the other hand, rhythm is related to the temporal 
parameters of gait and animal models have demonstrated the involvement of central pattern 
generators within the cervical and lumbar regions of the spinal cord (Marder & Calabress, 
1996). Temporal parameters of gait, such as duration of stride and swing, tend to be 
resistant to L-DOPA treatment (Blin et al., 1991, Lord et al., 2013). Variability refers to 
the step-to-step fluctuations and appears to also be L-DOPA resistant (Blin et al., 1991). 
Furthermore, current literature presents conflicting conclusions on the response of gait to 
STN-DBS. Some studies report an improvement in certain aspects of gait with long term 
STN-DBS treatment (Krack et al., 2003; Cantiniaux et al., 2010; Zibetti et al., 2011), 
whereas contradictory studies report no benefit or even worsening of gait (Kelly et al., 
2006; Kelly et al., 2010).  
Overall, gait dysfunction in PD directly affects mobility, which can severely impair a 
patient’s quality of life. Thus, there is an ongoing need to dissect the specific parameters 
of gait and potential effects of intervention to understand the true complexity of gait.  
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1.4.2  Gait Assessment Tools for Animal Models 
Currently, there are many behavioural tests available to investigate different aspects of gait 
in rodent models, and each are associated with its own strengths and weaknesses. The 
cylinder test, used to measure forelimb use, akinesia and asymmetry, is limited by the fact 
that it is manually scored and restricted to only forelimbs (Tillerson et al., 2001; Iancu, 
Mohapel, Brundin, & Paul, 2005). Other tests that evaluate forced locomotion, such as the 
rotarod and treadmill, allow for investigation of more dynamic gait parameters, but do not 
dissect specific changes in walking patterns (Iancu et al., 2005, Monville et al., 2006). 
Lastly, footprint tracking, in which an animal walks down a paper after their paws are 
dipped in ink, only measures static gait parameters (De Medinaceli, Freed, & Wyatt, 1982). 
In more recent years, the introduction of the CatWalk gait analysis system has provided for 
an automated and simultaneous quantification of many static and dynamic aspects of gait 
during voluntary walking (Hamers, Lankhorst, van Laar, Veldhuis, & Gispen, 2001). The 
CatWalk apparatus consists of a long-enclosed walkway designed to allow animals to 
traverse freely at their natural speed from one side to the other. The walkway comprises of 
a glass plate floor illuminated by a green light. As the paws of the animal contacts the glass 
floor, the green light is scattered against a red backdrop. This scattering of light is captured 
by a high speed video camera mounted below the glass. Based on the captured data 
(position, pressure and surface area) of each footprint, the CatWalk software is able to 
measure many parameters of gait. A sample of raw CatWalk data to illustrate the light 
scattering technique of this apparatus is provided in Appendix 2.  
Several studies have demonstrated that Catwalk is a reliable tool in assessing gait for rodent 
models of many neurodegenerative disorders including PD (Vlamings et al., 2007; Chuang 
et al., 2010; Vandeputte et al., 2010). Specifically, this device has been validated for 
measuring abnormalities in gait and locomotion in the 6-OHDA rodent model of PD 
(Westin, Janssen, Sager, & Temel, 2012; Zhou et al., 2015). A list of gait parameters 





Table 1 – Definition of Gait Parameters 
Parameter Definition 
Average Speed (cm/s) Distance traversed on the walkway divided by time 
Body Speed Variation 
(%) 
Difference between body speed and average speed 
divided by average speed 
Cadence (steps/s) Number of steps taken per second 
Duty Cycle (%) Stand as a percentage of step cycle  
Initial Dual Stance (s) 
Duration of the first step in a step cycle of a paw that the 
contralateral paw also contacts the walkway 
Max Contact Area (cm2) Maximum area of a paw that contacts the walkway 
Mean Intensity Mean pressure of a paw that contacts the walkway 
Single Stance (s) 
Duration of contact for a single paw when the 
contralateral paw is in swing 
Stand (s) Duration of contact of a paw with the walkway  
Step Cycle (s) Duration of two consecutive contacts of the same paw 
Stride Length (cm) 
Distance between two consecutive placements of the 
same paw 
Swing (s) Duration of no contact of a paw with the walkway  
Swing Speed (cm/s) Speed of a paw during swing 
Terminal Dual Stance (s) 
Duration of the second step in a step cycle of a paw that 
the contralateral paw also contacts the walkway 
 
1.4.3  Gait Changes in the 6-OHDA Model of Parkinson’s Disease 
A study by Zhou et al. (2015) investigated the differences in gait deficits of different 
unilateral 6-OHDA rat models of PD. Specifically, this study analyzed the changes in static 
and dynamic gait parameters after administration of 6-OHDA into the MFB, CPu or SNpc. 
The authors observed only mild gait impairment in the CPu lesioned animals, but 
significant impairments in the MFB and SNpc groups. The MFB lesioned animals 
demonstrated greater impairment than the SNpc lesioned rats and thus, the authors 
suggested that 6-OHDA lesioning of the MFB is the most appropriate rodent model to 
study gait dysfunction. Specifically, experiments by Chuang et al. (2010) and Zhou et al. 
(2015) demonstrated that approximately 4 weeks following 6-OHDA lesioning of the 
MFB, animals displayed a decrease in max contact area, mean intensity, stride length and 
swing speed and an increase in stand, swing, step cycle, duty cycle and terminal dual 
stance. In addition, significant differences in contralateral compared to ipsilateral limbs 
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were observed for static gait parameters, specifically max contact area and mean intensity. 
However, these asymmetric differences were not detected for dynamic gait parameters.  
Moreover, additional studies have associated the gait changes observed in rodent PD 
models to certain clinical phenotypes of PD patients (Chuang et al., 2010; Westin et al., 
2012; Zhou et al., 2015). Hypokinesia and an increase in muscle rigidity is reflected by the 
reduction in stride length and swing speed in PD rats (Zhou et al., 2015). This is similar to 
the clinical signs that are often seen in PD patients who take smaller steps while walking. 
Furthermore, an increase in stand and swing duration, along with a decrease in swing speed, 
contribute to an overall reduction in average speed of hemi-PD rodents (Lee, Hsieh, Liang, 
Yeh, & Chen, 2012; Zhou et al., 2015). These changes are reflective of the decrease in pace 
seen in PD patients.  
In sum, unilateral injection of 6-OHDA into the MFB produces evident and stable gait 
deficits that are well-characterized and validated by the CatWalk apparatus. Therefore, the 
CatWalk test was used to analyze changes in static and dynamic gait parameters of 6-
OHDA lesioned rodents in this research project.   
 
1.5 Botulinum Neurotoxins 
1.5.1  Overview and Mechanism 
Botulinum neurotoxins (BoNTs) are a family of metalloproteases synthesized by different 
strains of the anaerobic bacteria, Clostridium botulinum (Ermengem, 1897; Hatheway, 
1989). This family comprises of seven antigenically distinct serotypes (BoNT-A to BoNT-
G), which target specific machinery at synaptic terminals to block the release of 
neurotransmitters (Burgen, Dickens, & Zatman, 1949; Lacy & Stevens, 1999). These 
neurotoxins exert their paralytic action by a multistep mechanism: 1) binding, 2) 
internalization, 3) membrane translocation and 4) proteolytic cleavage (Simpson, 1981; 
Montecucco, Papini, & Schiavo, 1994).  
BoNTs are secreted as an inactive precursor consisting of a single 150 kDa polypeptide 
chain, which is subsequently cleaved to yield the active neurotoxin. The active form 
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contains a 100 kDa heavy (H) chain and a 50 kDa light (L) chain linked together by a single 
disulphide bond (Sakaguchi, 1982; Montecucco & Schiavo, 1995). The carboxy-terminal 
of the heavy chain (HC) mediates the uptake of the toxin into axon terminals by specific 
receptor binding and the amino-terminal (HN) facilitates membrane translocation (Lacy & 
Stevens, 1999; Rossetto & Montecucco, 2008). Specifically, the HC of BoNT-A binds to 
isoforms A-C of the synaptic vesicle protein 2 (SV2) receptor and to the GT1B 
polysialoganglioside (Dong et al., 2006; Kozaki et al., 1998). After binding to the SV2 
receptor, BoNT-A utilizes synaptic vesicle recycling to mediate its endocytosis into 
presynaptic terminals (Simpson, 2004). Following internalization, the reduction in pH 
leads to a conformational change in which HN acts as a transmembrane chaperone for the 
L chain to translocate pass the vesicle membrane into the cytosol (Koriazova & Montal, 
2003). Through a reduction of the disulphide bond, the L chain is released into the cytosol, 
where it displays its enzymatic effects by cleaving specific components of the synaptic 
vesicle docking-fusion apparatus known as the soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) complex (Schiavo, Matteoli, & Montecucco, 2000). 
Synaptic SNARE proteins are essential for neuroexocytosis and their cleavage by BoNTs 
results in the inhibition of neurotransmitter release. BoNT-A acts as zinc-dependent 
endopeptidase that targets synaptosomal-associated protein 25 (SNAP-25) of the SNARE 
complex (Blasi et al., 1993). Specifically, BoNT-A cleaves SNAP-25 by hydrolyzing the 
Gln197-Arg198 peptide bond (Schiavo et al., 1993). The cleaved SNAP-25 is now unable to 
mediate fusion of vesicles carrying neurotransmitters to the presynaptic membrane and 
thus, neuroexocytosis is impaired.    
 
1.5.2  BoNT-A Effects in Non-Cholinergic Systems  
The effect of BoNT-A has been best studied in its ability to block the release of the 
neurotransmitter acetylcholine (Simpson, 1981). However, BoNT-A is not limited to 
inhibiting acetylcholine release, and has been demonstrated to also inhibit the release of 
other neurotransmitters from synaptosomes, including glutamate, glycine, noradrenaline, 
and dopamine (Sanchez-Prieto et al., 1987; Bigalke, Heller, Bizzini, & Habermann, 1981;  
Ashton & Dolly, 1988; McMahon et al., 1992). A study by Sanchez-Prieto (1987) 
demonstrated that BoNT-A significantly inhibits Ca2+ dependent glutamate exocytosis 
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from cerebral cortical synaptosomes. In this in vitro experiment, the authors found that 
inhibition of glutamate exocytosis by BoNT-A develops over 2 hours. Furthermore, a 
similar study by Bigalke et al. (1981) demonstrated that BoNT-A significantly inhibits 
evoked release of noradrenaline and glycine from particulate preparations of rat brain and 
spinal cord tissue. The extent of noradrenaline and glycine inhibition was very similar to 
that of cholinergic blockage, with approximately 80% inhibition at 10 ug/mL of BoNT-A. 
In contrast, inhibition of GABA by BoNT-A was drastically lower and required a 
significantly higher dose (by approximately five-fold) to achieve comparable levels of 
inhibition to that of acetylcholine. Moreover, a study by Ashton and Dolly (1988) also 
demonstrated that BoNT-A was significantly weaker in its maximum ability to impede 
GABA release compared to acetylcholine release (40% compared to 90% neurotransmitter 
inhibition). These studies were further supported by work conducted by McMahon et al. 
(1992), which compared the inhibitory effect of tetanus toxins to BoNTs on a variety of 
neurotransmitters and neuropeptides. The authors concluded that BoNT-A was able to 
significantly inhibit release of glutamate from synaptosomes, whereas only tetanus toxin 
additionally inhibited the release of GABA, aspartate, and met-enkephalin. All of this 
experimental data offers support to suggest that GABAergic terminals are considerably 
less sensitive to BoNT-A than glutamatergic terminals.  
The molecular basis for this differential sensitivity of BoNT-A on specific terminals 
remains unclear (Verderio et al., 2006; Verderio et al., 2007). A series of experiments 
conducted by Verderio et al. postulate that the relative resistance of GABAergic synapses 
to BoNT-A may be due to a differential expression of SNAP-25. In both cultured neurons 
and brain slices, hippocampal GABAergic terminals lacked the classical SNAP-25 of the 
SNARE complex (Verderio et al., 2004). This absence of SNAP-25 was thought to underlie 
its resistance to BoNT-A because exogenous expression of SNAP-25 in GABAergic 
neurons induced sensitivity to BoNT-A (Verderio et al., 2007). Although this work was 
conducted in hippocampal neurons, a comprehensive neuroanatomical distribution of 
SNAP-25 was mapped in an entire rodent brain by Oyler et al. in 1989. They reported 
relatively lower levels of SNAP-25 present in the BG compared to other brain regions. 
Furthermore, differences in intrinsic calcium dynamics between glutamatergic and 
GABAergic synapses also contribute to the preferential inhibitory action of BoNT-A 
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(Grumelli, Corradini, Matteoli, & Verderio, 2010). The reduced effectiveness of BoNT-A 
in GABAergic synapses is attributable to the higher evoked calcium responsiveness of 
these inhibitory neurons (Grumelli et al., 2010; Akaike et al., 2010). Finally, a chief 
difference between glutamatergic and GABAergic terminals that most likely underlies the 
differential sensitivity of BoNT-A is their expression of the SV2 receptor, which is 
necessary for the internalization of BoNT-A (Simpson, 2004). Quantitative analysis of 
SV2B in glutamatergic versus GABAergic axon terminals demonstrated 80% 
colocalization of SV2B with a glutamatergic marker, whereas only 15% colocalization of 
SV2B with a GABAergic marker (Bragina et al., 2012). The reduced levels of the SV2 
receptor in GABA terminals significantly contributes to BoNT-A resistance in these 
inhibitory neurons.    
Regardless of the molecular mechanism underlying the preferential inhibitory action of 
BoNT-A on cholinergic and glutamatergic rather than GABAergic terminals, this 
differential sensitivity can be exploited to treat pathologies that result because of 
imbalances in excitatory and inhibitory neurotransmission. This includes the changes in 
BG circuitry seen in PD, as previously described in Chapter 1.2.2.  
 
1.5.3  Use of BoNT-A for Parkinson’s Disease 
With its ability to suppress cholinergic activity at the neuromuscular junction, BoNT-A has 
been commonly used clinically as a peripheral treatment for tremor in PD (Kim, Yiannikas, 
Mahant, Vucic, & Fung, 2014; Samotus, Rahimi, Lee, & Jog, 2016; Zakin & Simpson, 
2017). As a clinical therapeutic, the peak effect of BoNT-A typically occurs at 4 weeks 
post-injection and repeated injections given every 3-4 months (Kim et al., 2014).    
Moreover, emerging research on rodents suggests a role for the direct administration of 
BoNT-A in the central nervous system (Hawlitschka et al., 2013; Mazzocchio & Caleo, 
2015). Several studies have shown that direct injection of BoNT-A in the spinal cord and 
brain can serve as a modulator for pain and PD, respectively (Chaddock et al., 2004; Wree 
et al., 2010). Studies by Wree et al. (2010) demonstrated that ipsilateral injections of 1-2 
ng of BoNT-A at the striatum could block cholinergic overactivation of GABAergic 
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medium spiny neurons in the 6-OHDA rat model of PD. By locally interrupting release of 
acetylcholine, apomorphine-induced rotational behaviour in hemiparkinsonian rats was 
abolished up to 6 months. A minimum dose of 100 pg of BoNT-A revealed beneficial but 
insignificant effects, whereas a maximum dose of 5 ng lead to occasional lethality. The 
behavioural effects of BoNT-A in 6-OHDA lesioned rats were further studied by Antipova 
et al. (2013). After 3 months of treatment with 2 ng of BoNT-A in the striatum, 
hemiparkinsonian rats showed an equalization of forelimb use (measured by the cylinder 
test) compared to untreated rats. However, no motor improvements were detected by the 
rotarod test or open field test following intrastriatal BoNT-A treatment.  
The results of these studies, along with several other experiments involving direct 
administration of BoNT in the brain, demonstrate that central injection of BoNT in rodents 
is not cytotoxic and offers an immense potential as a novel therapeutic to 
neurodegenerative diseases, such as PD.    
 
1.6 Rationale 
1.6.1  Overview 
With over 7 million people affected by PD globally, there is an ongoing need to research 
the mechanisms underlying its pathogenesis and to identify novel management and 
therapeutic interventions (Chapter 1.1.1). PD is characterized by the degeneration of 
dopaminergic neurons in the SNpc (Chapter 1.1.2), but the exact molecular mechanisms 
underlying this neuronal death remain unclear (Chapter 1.1.3). This neurodegenerative 
disorder is associated with both motor and non-motor symptoms (Chapters 1.1.4 and 1.4.1), 
which are currently managed by a combination of medications and/or surgical options 
(Chapter 1.1.5). Current interventions offer symptomatic relief but have not been able to 
slow the rate of progression of PD, nor have been confirmed as displaying neuroprotective, 
neurorescuing or neurorestorative effects. There is still an unmet need for exploring novel 




In PD, the death of dopaminergic neurons in the SNpc leads to changes in BG circuitry 
(Chapter 1.2.2.). Current concepts of BG circuitry propose that loss of striatal dopamine in 
PD results in an imbalance of the direct and indirect pathways, which contribute to greater 
inhibitory outflow to the thalamocortical motor centers. Amongst this intricate network, 
the STN, the only glutamatergic BG nuclei, plays an important role in the facilitation or 
inhibition of movement. It is well accepted that in PD, the STN is considered overactive 
due to its increase in glutamatergic outflow to the output nucleus, the GPi (rodent 
equivalent: EPN). Thus, the STN has become a key target site for implementing 
interventions to treat and manage symptoms of PD. Novel pharmacological or surgical 
therapies that are able to reduce STN neuronal overactivity or impair glutamate 
transmission at its target structures, such as the GPi/EPN may be highly promising in the 
treatment of PD. 
BoNT-A is a commonly used toxin in medicine, cosmetics and research due to its ability 
to block the release of acetylcholine from axon terminals. The ability of BoNT-A to cleave 
SNAP-25 of the SNARE complex to prevent neuroexocytosis has been extensively studied 
and is already well-established (Chapter 1.5.1). There is strong research to support the fact 
that BoNT-A has the ability to impair release of other neurotransmitters besides 
acetylcholine (Chapter 1.5.2). This includes a preference for glutamatergic terminals and a 
reduced effect of GABAergic terminals. In the past decade, there has been more and more 
research to investigate the possibility of direct BoNT-A injections in the brain (Chapter 
1.5.3). Central injections of BoNT-A have been demonstrated to be safe in rodents and 
promising for a variety of diseases, including PD. 
Central administration of BoNT-A offers immense potential as a novel therapeutic for PD, 
as it provides many of the unmet needs and criteria discussed throughout this chapter. 
Direct injection of BoNT-A at the GPi/EPN could preferentially target the incoming 
overactive projections of glutamate from the STN to the EPN without interfering with 
afferent GABAergic projections. As with most preclinical studies, this work could be 
studied in an animal model of PD (Chapter 1.3.1). Out of the available models of PD, 
unilateral lesioning of the MFB with 6-OHDA in rats was chosen as the hemiparkinsonian 
model best suited to conduct this research project (Chapter 1.3.3). Both motor and gait 
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dysfunction in this PD model has already been well characterized by numerous behavioural 
studies (Chapters 1.3.3 and 1.4.3) and thus, the subsequent changes following BoNT-A 
administration in this model can be readily detected and studied.  
 
1.6.2  Hypothesis 
It was hypothesized that administration of BoNT-A at the EPN would have modulated 
glutamate release from the STN, which would have consequently led to changes in BG 
circuitry to improve motor impairments of a hemiparkinsonian animal.  
 
1.6.3  Objectives  
Overall, this project aimed to assess the molecular and behavioural effects of BoNT-A 
injections at the EPN of the unilateral 6-OHDA rat model of PD. The objectives of this 
study were as follows:  
1) To determine changes in locomotion and gait by the CatWalk apparatus following 
intra-EPN administration of BoNT-A 
2) To evaluate changes in drug induced rotations by the apomorphine rotation test 
following intra-EPN administration of BoNT-A 
3) To establish an optimal dose of BoNT-A for intra-EPN  
4) To measure the temporal pattern of efficacy of intra-EPN BoNT-A   
5) To determine neuroanatomical and molecular changes of the EPN by 
immunohistochemistry following direct administration of BoNT-A  
 
1.6.4  Predictions 
The predictions were as follows: 
1) Direct administration of BoNT-A at the EPN would have improved gait and motor 
performance of 6-OHDA lesioned animals 
2) Injection of BoNT-A at the EPN would have reduced apomorphine-induced 
pathological rotations of 6-OHDA lesioned rodents  
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3) A dose in the ‘ng’ range would have been necessary to mediate the BoNT-A 
induced behavioural improvements 
4) The effects of BoNT-A would have been transient, with restoration of both 
structural and behavioural alterations 
5) The changes in behaviour would have been caused by a differential effect of BoNT-
A on glutamatergic projections from the STN and GABAergic terminals from the 




Chapter 2  
2 Materials and Methods 
This chapter outlines the materials and methods used to conduct this study. Figure 2 
provides a summary of the timeline of the experimental protocol. All experimental work 
was performed under the guidelines of the Animal Care Committee at Western University 
and followed the approved Animal Use Protocol #2015-087 (Appendix 1).  
 
Figure 2 – Experimental timeline 
 
2.1 Experimental Animals 
Adult male Sprague-Dawley rats (Charles River Canada), weighing 250-300 grams at the 
time of the first surgery, were used in this study. All experimental work was conducted in 
accordance with the guidelines of the Animal Care Committee at Western University. This 
study was approved by the committee (AUP 2015-087) and all regulatory materials 
regarding the use of BoNT-A in animals was also approved. Animals were housed in 
standard cages in a temperature-controlled room (22±1°C) under 12 hr light/12 hr dark 
conditions with controlled access to food and water. Food restriction was used to regulate 
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the weight of the animals throughout the prolonged study. Animals were fed 15-20 grams 
of food daily to limit weight gain to approximately 20 grams per week.  
The breakdown of experimental animals is represented in Figure 3. Animals were divided 
into four experimental groups: (1) sham lesioned animals receiving vehicle (n=12), (2) 
sham lesioned animals receiving BoNT-A (0.5 ng) (n=12), (3) 6-OHDA lesioned animals 
receiving vehicle (n=12), and (4) 6-OHDA lesioned animals receiving BoNT-A (n=24). 
All groups were further subdivided into a set of animals to be sacrificed at 1 month post-
BoNT-A treatment (n=4) for immunostaining and a set of animals to be sacrificed at 3 
months post-BoNT-A treatment (n=8) following completion of behavioural studies. Group 
4 animals were further subdivided into those that were injected with a low dose (0.05 ng) 
of BoNT-A (n=8) and those that were injected with a high dose (0.5 ng) of BoNT-A (n=16). 
An additional set of group 4 animals injected with a high dose were sacrificed at 1 week 
post-BoNT-A treatment (n=4).   
 




2.2 6-OHDA Lesioning of the MFB 
Hemiparkinsonism was induced by unilateral injection of 6-OHDA into the right MFB. All 
animals were administered desipramine hydrochloride (25 mg/kg, IP.; Sigma) 30-60 
minutes before 6-OHDA infusion to protect noradrenergic terminals. Animals were 
anaesthetized with a mixture of ketamine (80 mg/kg, IP) and xylazine (5 mg/kg, IP) and 
placed on a stereotaxic apparatus (Kopf Instruments). Sedation was monitored using a 
gentle toe pinch withdrawal reflex and thermoregulation was provided by heat lamp and 
monitored by a rectal thermometer. The head of the animal was shaved by an electric razor 
and the surgical site was cleaned with surgical soap, isopropyl alcohol and a chlorohexidine 
solution before incision. A midline skin incision (2 cm) was made and all soft tissue from 
the surface of the skull was removed to expose the skull. All stereotaxic coordinates were 
calculated from Bregma according the rat brain atlas of Paxinos and Watson (2009). A burr 
hole of approximately 1 mm was drilled to introduce a 31G injection cannula (PlasticsOne) 
at the right MFB (AP -1.8, L 2, DV 8.3) (Appendix 3). The cannula was attached to a 
Hamilton syringe by polyethylene tubing for the delivery of 6-OHDA. A total volume of 4 
µL of a 6-OHDA solution (8 µg/rat: 4 µL of 100 mg/50 mL 6-OHDA dissolved in 0.9% 
saline containing 0.1% ascorbic acid; Sigma) was injected over 4 minutes and the cannula 
was left in place for an additional 5 minutes before being slowly withdrawn. Sham lesioned 
control animals received an equivalent volume of 0.9% saline containing 0.1% ascorbic 
acid. 
 
2.3 BoNT-A Injection at the EPN 
Four weeks after 6-OHDA surgery, successfully lesioned rats and controls were subjected 
to BoNT-A injection. Stereotaxic surgery was performed under ketamine/xylazine 
anesthesia and surgical preparation was completed consistent with the 6-OHDA surgery. 
Administration of BoNT-A (List, Campbell, USA) at the right EPN (AP -2.5, L 3.0, DV 
7.7) was delivered through a 31G injection cannula attached to a Hamilton syringe by 
polyethylene tubing (Appendix 3). A total volume of 0.5 µL of a BoNT-A solution was 
injected over 5 minutes and the cannula was left in place for an additional 5 minutes before 
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being slowly withdrawn. Animals received either a high dose at 0.5 ng of BoNT-A (0.5 µL 
of 1 ng/uL BoNT-A dissolved in phosphate buffered saline (PBS) containing 0.1% bovine 
serum albumin (BSA)) or a low dose at 0.05 ng of BoNT-A (0.5 µL of 100 pg/uL BoNT-
A dissolved in PBS containing 0.1% BSA). Control animal received an equivalent volume 
of PBS with 0.1% BSA.  
 
2.4 Behavioural Tests 
Behavioural studies were performed before and after BoNT-A injection to evaluate the 
potential changes in motor activity and gait following treatment.  
 
2.4.1  Apomorphine-Induced Rotation Test 
Three weeks after 6-OHDA surgery and 1 week prior to BoNT-A injection, the 6-OHDA 
lesion quality was tested by apomorphine-induced rotations. Since the right MFB was 
unilaterally lesioned, it was expected that injection of apomorphine lead to contralateral 
rotations away from the lesioned side (see Chapter 1.3.3 for details).  
Following injection of apomorphine (0.25 mg/kg, SC.; Sigma), rats were placed 
individually in empty colony cages with a video camera recording their behaviour for 30 
minutes. Subsequently, rotations were counted over 15 minutes of video footage to 
determine the average rotation per minute for each rat. Only rats showing more than seven 
contralateral rotations per minute were used in subsequent experiments as parkinsonian 
animals. This drug-induced rotation test was repeated at 1 week, 1 month and 3 months 
after administration of BoNT-A treatment.  
 
2.4.2  CatWalk Studies 
The CatWalk XT (Noldus, Wageningen, Netherlands) apparatus was used to observe and 
assess gait of voluntarily moving rats (see Chapter 1.4.2 for details). All animals were 
trained to cross the walkway in a consistent manner prior to any experimentation. Training 
was performed by placing a sucrose pellet at the end of the walkway in the home cage of 
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the animal. Animals were then placed on the open end of the platform and allowed to freely 
traverse the walkway towards their home cage. A gait trial was considered successful if the 
animal completes the walk across the whole platform within 8 seconds and without any 
turns. In each session, a minimum of three compliant trials for each rat was recorded and 
non-compliant trials were excluded from the study. 
Training and baseline testing was performed for all rats one week prior to 6-OHDA lesion. 
Three weeks after 6-OHDA surgery and one week prior to BoNT-A injection, animals were 
retested on the CatWalk to assess deviations in gait and locomotion. Following BoNT-A 
treatment, CatWalk testing was repeated at 1 week, 1 month and 3 months for all animal 
groups. 
 
2.5 Perfusion and Tissue Collection 
After completion of behavioural studies, animals were sacrificed with an overdose of 
sodium pentobarbital (250 mg/kg; IP). Once all reflexes were gone, a transcardial perfusion 
was performed. An abdominal incision was made to enter the body cavity. This opening 
was extended through the diaphragm, pass the rib cages and into the thoracic cavity to 
expose the heart. A needle attached to a pump was inserted through the left ventricle into 
the aorta and an opening was made in the right atrium. 400 mL of 0.9% saline was pumped 
through the animal to remove the blood, followed by 400 mL of 4% of paraformaldehyde 
solution to fix the tissue. After the perfusion, brains were removed from the skull and 
postfixed in the perfusion solution for 24-48 hours. Brains were then transferred and placed 
in 25-30% sucrose for at least 48 hours for cryoprotection.  
 
2.6 Immunohistochemistry 
2.6.1  Immunofluorescence Staining 
Following cryoprotection, brains were cut into blocks containing the region of interest. 
Blocks were mounted with optimal cutting temperature compound and coronal brain 
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sections of 40 µm thickness were prepared by a freezing microtome. Every tenth section 
was collected for immunohistochemical staining. Sections were washed three times with 
phosphate buffer (PB) and then, blocked in PB containing 0.1% Triton X-100, 15% BSA 
and animal serum (corresponding to the secondary antibody) for 1 hour at room 
temperature on a rotator. Primary antibodies were diluted in distilled H2O containing 15% 
BSA and animal serum, and incubations were performed overnight at room temperature on 
a rotator. Refer to Table 2 for a list of primary antibodies used in this study. Following 
primary antibody incubation, sections were washed three times with PB and either stained 
with an Alexa Fluor conjugated secondary antibody (Invitrogen by Thermo Fisher 
Scientific) or with a biotinylated secondary antibody (Vector Laboratories) for 1 hour at 
room temperature on a rotator. Alexa Fluor 594- conjugated donkey anti-mouse secondary 
antibody, biotinylated goat anti-mouse secondary antibody and/or biotinylated goat anti-
guinea pig antibody were diluted at 1:200 in PB containing 15% BSA and animal serum. 
After three washes in PB, sections previously incubated with a biotinylated secondary 
antibody were amplified using the avidin-biotin complex method (Vectastain Elite ABC-
HRP Kit, Vector Laboratories) for 1 hour at room temperature on a rotator. Sections were 
washed three times with PB and further amplified by the tyramide signal amplification 
method (TSA Biotin System, PerkinElmer) for 10 minutes at room temperature. After three 
washes in PB, fluorescein avidin DCS (Vector Laboratories) was diluted at 1:250 in PB 
and sections were incubated for 1.5 hours at room temperature on a rotator. Sections were 
washed a final three times before being mounted on 1 mm thick Superfrost plus slides 
(VWR International) and sealed with No. 1 cover glasses (VWR International) with 
Vectashield antifade mounting medium (Vector Laboratories).  
 
2.6.2  TH Staining 
For verification of unilateral 6-OHDA lesioning, staining for tyrosine hydroxylase (TH) at 
the striatum and substantia nigra was performed. All the same steps as immunofluorescence 
staining were performed, up to and including amplification with the avidin-biotin complex 
method. Following three washes, TH was detected by the 3,3’-diaminobenzidine method 
for 5 minutes (Sigma-Aldrich). Sections were washed a final three times before being 
mounted on 1 mm thick Superfrost plus slides (VWR International). Sections were then 
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dehydrated and cleared by transferring slides in increasing concentration of ethanol (75% 
to 95% to 100% (1) to 100% (2)) for 2 minutes each, followed by two consecutive washes 
in 100% xylene for 5 minutes. Finally, coverslips were added and sealed with 
SHUR/Mount xylene-based liquid mounting medium (Triangle Biomedical Sciences Inc).  
Table 2 – List of Primary Antibodies for Immunostaining 
Antibody Manufacturer  Catalog # Clonality Origin Dilution 
anti-GAD67 EMD Millipore MAB5406 Monoclonal Mouse 1:500 
anti-GFAP Sigma Aldrich G3893 Monoclonal Mouse 1:250 
anti-synaptophysin Sigma Aldrich S5768 Monoclonal Mouse 1:2000 
anti-TH Sigma Aldrich T1299 Monoclonal Mouse 1:250 





2.6.3  Microscopy 
For immunofluorescence, images were acquired on a Leica TCS SP8 confocal microscope 
through a HC PL APO 20x/0.7 CS, HC PL APO 40x/1.30 oil CS2 or HC PL APO 63x/1.40 
oil CS2 objectives using an excitation wavelength of 488 nm or 594 nm by a 20 mW AOTF 
diode laser. For each antibody, a minimum of 3 coronal sections per animal were analyzed 
in order to analyze a minimum range of 1200 µm in depth. For each section of the EPN, an 
area of 580x580 m was analyzed at 20x, 290x290 m at 40x and 193x193 m at 60x. 
Images were taken at a z-stack of 33 sections with section interval of 0.6 m (20x), 0.3 m 
(40x) or 0.3 (63x). Acquisition parameters were kept consistent for sections stained with 
the same antibody. Each series of z-stack images were processed with a maximum intensity 
projection tool on ImageJ to create a final image with pixels containing the maximum value 
of the whole stack. The mean intensity of each whole stack was then measured by ImageJ.  
For TH staining, images were acquired on a Leica TCS SP8 confocal microscope through 
a HC PL Fluotar 5x/0.15 dry objective. A minimum of 3 coronal sections per animal were 
analyzed in order to analyze a minimum range of 1200 µm in depth. Images of complete 




2.7 Statistical Analysis 
All data is expressed as mean ± standard error of mean. Statistical analysis was performed 
using GraphPad Prism 7. All groups were tested with a D’Agostino and Pearson normality 
test. For analysis of CatWalk data, a comparison of the animals before and after BoNT-A 
injection was performed with a repeated measures one-way ANOVA followed by a 
Tukey’s post hoc test. For immunofluorescence staining, a comparison of animal groups 
was performed with a Kruskal-Wallis test followed by a Dunn’s post hoc test. Specifically, 
for GFAP staining, a comparison between untreated and treated rats was analyzed by an 
unpaired Student’s t-test. A critical value for significance of p<0.05 was used throughout 
the study.   
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Chapter 3  
3 Results 
3.1 Results of the Apomorphine Rotation Test  
As expected, subcutaneous injection of apomorphine in sham lesioned rats did not induce 
any significant rotational behaviour (Timepoint 0 in Figure 4 A and B). Apomorphine in 
6-OHDA lesioned animals caused contralateral rotations away from the lesion, with an 
average of 8.305 rotations per minute in all successfully 6-OHDA lesioned animals 
(Timepoint 0 in Figure 4 C-E).  
Rotational behaviour was tested again at 1 week, 1 month and 3 months following BoNT-
A injection into the ipsilateral EPN. Control vehicle (PBS) injections into the EPN did not 
cause any apomorphine-induced rotations in sham lesioned rats (Figure 4 A), nor did it 
abolish the pathological contralateral rotations in 6-OHDA lesioned animals (Figure 4 C). 
Specifically, 6-OHDA animals treated with vehicle injections continued to rotate on 
apomorphine at an average of 8.358 rotations per minute at 1 week, 8.400 at 1 month, and 
8.758 at 3 months. This was insignificantly different from the 8.242 rotations prior to 
treatment. Injection of 0.5 ng of BoNT-A in sham lesioned animals had no effect on 
rotational behaviour (i.e. it did not halt nor induce any pathological rotations) (Figure 4 B). 
Administration of 0.5 ng of BoNT-A in 6-OHDA lesioned animals significantly abolished 
the apomorphine-induced rotations completely at 1 week and 1 month post-treatment 
(F(1,10) = 152.7, p < 0.0001) (Figure 4 D). Comparison of apomorphine-induced rotations 
of 6-OHDA lesioned rats prior to and following 0.5 ng BoNT-A administration to the EPN 
was significant at 1 week (p = 0.0001) and 1 month (p = 0.0001), but was insignificant at 
3 months (p = 0.0603). Hemi-PD rats only demonstrated 1.125 rotations per minute at 1 
week and 1.080 at 1 month post-treatment. However, the number of rotations per minute 
returned up to 7.317 after 3 months following BoNT-A injection, which was not 




Dose-response studies have indicated that injections of the lower doses (0.05 ng) of BoNT-
A in 6-OHDA lesioned animals mildly reduced the average number of rotations at 1 week 
(F(2,19) = 4.734, p = 0.0140), but failed to abolish rotations at 1 month or 3 months (Figure 
4 E). The initial reduction at 1 week was weakly significant (p = 0.0344) and became 







Figure 4 – Apomorphine-induced rotation of hemi-PD rats treated with BoNT-A  
Changes in apomorphine (0.25 mg/kg) induced rotation after administration of BoNT-A at 
the EPN (n=8 per group). Control lesioned rats showed no rotations after vehicle (A) or 
BoNT-A injection (B). Vehicle injection had no effect on pathological rotations in 6-
OHDA lesioned rats (C). 0.5 ng of BoNT abrogated rotations in 6-OHDA rats at 1 week 
and 1 month, but rotations re-emerged at 3 months (D). 0.05 ng of BoNT reduced rotations 
at 1 week but failed to reduce pathological rotations at 1 month and 3 months (E). All 
results are presented as mean ± sem. Asterisks indicate significant changes compared to 
initial values (0) according to repeated measures one-way ANOVA and post hoc Tukey 




3.2 Results of the CatWalk Apparatus  
3.2.1  Changes in Average Speed  
The average speed of animals was determined by using the CatWalk apparatus prior to and 
following 6-OHDA lesioning of the right MFB. As expected, sham lesioning of the MFB 
did not significantly change the average speed of animals compared to their naïve state 
(naïve vs timepoint 0 in Figure 5 A and B). On the other hand, 6-OHDA lesioning of the 
MFB significantly reduced the average speed of animals from 57.1 cm/s for naïve animals 
to 34.4 cm/s following lesioning (naïve vs timepoint 0 in Figure 5 C [F(2,14) = 34.87, p = 
0.0046]) and from 51.48 cm/s for naïve animals to 36.39 cm/s following lesioning (naïve 
vs timepoint 0 in Figure 5 D [F(2,17) = 44.96, p = 0.0017]).  
Average speed was tested again at 1 week, 1 month and 3 months following BoNT-A 
injection into the ipsilateral EPN. Control vehicle (PBS) injections at the EPN did not alter 
the average speed of sham lesioned rats (Figure 5 A), nor did it improve the impaired speed 
of 6-OHDA lesioned animals (Figure 5 C). More specifically, 6-OHDA animals treated 
with vehicle injections continued to walk at an average speed of 26.49 cm/s at 1 week, 30.5 
cm/s at 1 month, and 31.11 cm/s at 3 months. This was not significantly different from the 
average speed of 34.4 cm/s prior to BoNT-A treatment. Furthermore, injection of 0.5 ng of 
BoNT-A did not significantly reduce or increase the average speed of sham lesioned 
animals (Figure 5 B).  
Importantly, administration of 0.5 ng of BoNT-A significantly improved the average speed 
of 6-OHDA lesioned animals at 1 week and 1 month post-treatment (F(2,17) = 44.96, p < 
0.0001) but the change was not significant at 3 months (Figure 5 D). 6-OHDA lesioned 
rats increased their average speed to 63.37 cm/s at 1 week (p < 0.0001) and to 63.74 cm/s 
at 1 month (p = 0.0003) post BoNT-A injection. However, their average speed reduced 
back to 35.24 cm/s at 3 months, which was similar to their average of 36.69 cm/s prior to 






Figure 5 – Average speed of hemi-PD rats treated with BoNT-A 
Changes in average speed after injection of 0.5 ng of BoNT-A at the EPN (n=8 per group). 
Experimental timepoints are reflected on the x-axis: naïve rats tested prior to any surgeries, 
6-OHDA (or sham lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) 
animals tested at 1 week, 1 month or 3 months following treatment. Control lesioned rats 
showed no changes in speed after vehicle (A) or BoNT-A injection (B). Vehicle injection 
did not improve the slowness of 6-OHDA lesioned rats (C). 0.5 ng of BoNT improved the 
slowness of 6-OHDA lesioned rats at 1 week and 1 month, but no effect was seen at 3 
months (D). All results are presented as mean ± sem. Asterisks indicate significant changes 
compared to pre-lesioned animals (C) or lesioned animals (D) according to repeated 









3.2.2  Changes in Body Speed Variation  
The CatWalk apparatus was also used to detect changes in body speed variation (a measure 
of consistency of walking speed). Unsurprisingly, sham lesions did not significantly alter 
the body speed variation of rodents compared to their naïve state (naïve vs timepoint 0 in 
Figure 6 A and B). However, the body speed variation of animals increased significantly 
following 6-OHDA lesioning, from 12.73% for naïve animals to 34.16% (naïve vs 
timepoint 0 in Figure 6 C [F(2,17) = 5.076, p = 0.0116]) and from 11.21% for naïve animals 
to 33.19% (naïve vs timepoint 0 in Figure 6 D [F(2,14) = 25.99, p < 0.0001]).  
After BoNT-A injection into the ipsilateral EPN, body speed variation was re-measured. 
Control vehicle (PBS) injections at the EPN did not change the body speed variation of 
sham lesioned rats (Figure 6 A), nor did it reduce the higher variation of 6-OHDA lesioned 
animals (Figure 6 C). 6-OHDA animals treated with PBS injections maintained a body 
speed variation of 33.76% at 1 week, 30.77% at 1 month, and 29.44% at 3 months, which 
was insignificant from the 34.16% variation prior to BoNT-A treatment. Likewise, 
injection of 0.5 ng of BoNT-A in sham lesioned animals had no effect on the body speed 
variation of sham lesioned animals (Figure 6 B).  
Notably, 0.5 ng of BoNT-A injected at the EPN significantly reduced the pathological body 
speed variation of 6-OHDA lesioned animals at 1 week and 1 month post-treatment 
(F(2,14) = 25.99, p < 0.0001), but the effect was insignificant at 3 months (Figure 6 D). 
After BoNT-A administration, the body speed variation of 6-OHDA lesioned rats 
decreased to 12.32% at 1 week (p = 0.0057) and 9.869% at 1 month (p = 0.0024). However, 
their body speed variation returned back to 31.52% at 3 months, which was insignificant 




Figure 6 – Body speed variation of hemi-PD rats treated with BoNT-A 
Changes in body speed variation after infusion of 0.5 ng of BoNT-A at the EPN (n=8 per 
group). Experimental timepoints are reflected on the x-axis: naïve rats tested prior to any 
surgeries, 6-OHDA (or sham lesioned) animals tested at week 0, and BoNT-A (or sham 
vehicle) animals tested at 1 week, 1 month or 3 months following treatment. Control 
lesioned rats showed no changes in body speed variation after vehicle (A) or BoNT-A 
injection (B). Vehicle injection did not reduce the increased body speed variation of 6-
OHDA lesioned rats (C). 0.5 ng of BoNT reduced the body speed variation of 6-OHDA 
lesioned rats at 1 week and 1 month, but no effect was seen at 3 months (D). All results are 
presented as mean ± sem. Asterisks indicate significant changes compared to pre-lesioned 
animals (C) or lesioned animals (D) according to repeated measures one-way ANOVA and 





3.2.3  Changes in Cadence  
The cadence (number of steps taken per second) was measured by the CatWalk apparatus 
before and after 6-OHDA lesioning of the MFB. As expected, sham lesioning of the MFB 
did not significantly change the cadence compared to their naïve state (naïve vs timepoint 
0 in Figure 7 A and B). On the other hand, 6-OHDA lesioning of the MFB significantly 
reduced the cadence of animals from 11.33 steps per second for naïve animals to 7.156 
steps per second following lesioning (naïve vs timepoint 0 in Figure 7 C [(F(3,25) = 36.75,  
p = 0.0004]) and from 11.11 steps per second for naïve animals to 7.368 steps per second 
following lesioning (naïve vs timepoint 0 in Figure 7 D [F(2,18) = 26.42, p = 0.0005]).  
Cadence was tested again at 1 week, 1 month and 3 months following BoNT-A injection 
into the ipsilateral EPN. Control vehicle (PBS) injections at the EPN did not alter the 
cadence of sham lesioned rats (Figure 7 A), nor did it increase the dysregulated cadence of 
6-OHDA lesioned animals (Figure 7 C). More specifically, 6-OHDA animals continued to 
walk with a cadence of 5.569 steps per second at 1 week, 6.55 steps per second at 1 month, 
and 6.124 steps per second at 3 months after PBS injections. This was insignificant from 
the cadence of 7.156 prior to BoNT-A treatment. Furthermore, injection of 0.5 ng of BoNT-
A did not significantly reduce or increase the cadence of sham lesioned animals (Figure 7 
B).  
Importantly, administration of 0.5 ng of BoNT-A significantly improved the cadence of 6-
OHDA lesioned animals at 1 week and 1 month post-treatment (F(2,18)= 26.42, p < 
0.0001), but was insignificant at 3 months (Figure 7 D). 6-OHDA lesioned rats increased 
their cadence to 11.14 steps per second at 1 week (p < 0.0001) and 11.94 steps per second 
at 1 month (p = 0.0024) post BoNT-A injection. These values are similar to their cadence 
of 11.11 steps per second in their naïve state. However, their cadence lowered to 7.099 
steps per second at 3 months, which was similar to their average of 7.368 steps per second 




Figure 7 – Cadence of hemi-PD rats treated with BoNT-A 
Changes in cadence after administration of 0.5 ng of BoNT-A at the EPN (n=8 per group). 
Experimental timepoints are reflected on the x-axis: naïve rats tested prior to any surgeries, 
6-OHDA (or sham lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) 
animals tested at 1 week, 1 month or 3 months following treatment. Control lesioned rats 
showed no changes in cadence after vehicle (A) or BoNT-A injection (B). Vehicle injection 
did not improve the reduction in cadence of 6-OHDA lesioned rats (C). 0.5 ng of BoNT 
increased the cadence of 6-OHDA lesioned rats at 1 week and 1 month, but no effect was 
seen at 3 months (D). All results are presented as mean ± sem. Asterisks indicate significant 
changes compared to pre-lesioned animals (C) or lesioned animals (D) according to 






3.2.4  Changes in Stand 
The CatWalk apparatus was used to measure the stand (duration of contact during a step 
cycle) for each paw (RF: right front, RH: right hind, LF: left front, and LH: left hind). Sham 
lesioning of the MFB did not significantly alter the stand of animals in any of their paws 
(naïve vs timepoint 0 in Figure 8 A and B). Furthermore, in these sham lesioned animals, 
no changes in stand were detected in any of the paws across all timepoints following 
vehicle injection (Figure 8 A) or 0.5 ng of BoNT-A (Figure 8 B) at the EPN. 
Consistent with previous studies, animals demonstrated a significant increase in stand 
following 6-OHDA lesioning of the MFB (naïve vs timepoint 0 in Figure 8 C and D). In 
fact, the duration of stand approximately doubled from an average of 0.2084 seconds to 
0.3901 seconds across all paws of 6-OHDA lesioned animals,.  
After vehicle injection at the EPN, stand across all paws of lesioned animals remained 
elevated for the following 3 months (Figure 8 C). On the contrary, following administration 
of 0.5 ng of BoNT-A at the EPN, stand significantly reduced across all paws of lesioned 
animals (Figure 8 D). At 1 week following BoNT-A infusion, stand significantly reduced 
to 0.1947 seconds for the RF (F(1,9) = 13.64, p = 0.0021), 0.2049 seconds for the RH 
(F(1,8) = 15.38, p = 0.0002), 0.1927 seconds for the LF (F(1,11) = 16.64, p = 0.0009) and 
0.2041 seconds for the LH (F(1,8) = 15, p < 0.0001). At 1 month following BoNT-A 
injection, stand remained significantly reduced at 0.2066 seconds for the RF (F(1,9) = 
13.64, p = 0.0003), 0.2146 seconds for the RH ((F(1,8) = 15.38, p < 0.0001), 0.1956 
seconds for the LF (F(1,11) = 16.64, p = 0.0013) and 0.2203 seconds for the LH (F(1,8) = 
15, p < 0.0001). However, at 3 months following BoNT-A, stand time returned to a longer 
duration at 0.4146 seconds for the RF, 0.4374 seconds for the RH, 0.3547 seconds for the 




Figure 8 – Stand of hemi-PD rats treated with BoNT-A 
Changes in stand after injection of 0.5 ng of BoNT-A at the EPN (n=8 per group). Paws 
were measured individually (RF: right front, RH: right hind, LF: left front, and LH: left 
hind) and organized on the x-axis. Experimental timepoints are reflected according to the 
legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham lesioned) animals tested 
at week 0, and BoNT-A (or sham vehicle) animals tested at 1 week, 1 month or 3 months 
following treatment. Sham lesioned rats showed no changes in stand after vehicle (A) or 
BoNT-A injection (B). Vehicle injection did not reduce the increased stand of 6-OHDA 
lesioned rats (C). 0.5 ng of BoNT decreased the stand of 6-OHDA lesioned rats at 1 week 
and 1 month, but no effect was seen at 3 months (D). All results are presented as mean ± 
sem. Asterisks indicate significant changes compared to pre-lesioned animals (C) or 
lesioned animals (D) according to repeated measures one-way ANOVA and post hoc 







3.2.5  Changes in Swing 
Swing, the duration of no contact during a step cycle, was also measured for each paw by 
the CatWalk apparatus. Sham lesioning of the MFB had no effect on the swing of any of 
the paws (naïve vs timepoint 0 in Figure 9 A and B). Additionally, in these sham lesioned 
animals, vehicle injection (Figure 9 A) or 0.5 ng of BoNT-A at the EPN (Figure 9 B) did 
not significantly alter swing in any of the paws across any timepoint.  
On the contrary, animals displayed a significant increase in swing following 6-OHDA 
lesioning of the MFB (naïve vs timepoint 0 in Figure 9 C and D). The time of swing across 
all paws increased from an average of 0.1471 seconds in naïve animals to 0.2001 seconds 
in successfully 6-OHDA lesioned animals.  
Following vehicle injection at the EPN of 6-OHDA lesioned animals, swing across all paws 
remained longer for the following 3 months (Figure 9 C). On the contrary, infusion of 0.5 
ng of BoNT-A at the EPN lead to a significant reduction of swing across all paws of 
lesioned animals (Figure 9 D). At 1 week following BoNT-A injection, swing significantly 
decreased to 0.1543 seconds for the RF (F(1,10) = 9.226, p = 0.001), 0.1412 seconds for 
the RH (F(2,14) = 14.5, p = 0.0133), 0.1588 seconds for the LF (F(1,13) = 6.704, p =  
0.0258) and 0.1365 seconds for the LH (F(1,11) = 20.59, p = 0.0046). At 1 month following 
BoNT-A infusion, swing remained significantly reduced at 0.1542 seconds for the RF 
(F(1,10) = 9.226, p = 0.0025), 0.1339 seconds for the RH (F(2,14) = 14.5, p = 0.0052), 
0.1511 seconds for the LF (F(1,13) = 6.704, p = 0.0154) and 0.1308 seconds for the LH 
(F(1,11) = 20.59, p = 0.0042). However, at 3 months following BoNT-A administration, 
the longer swing duration of lesioned animals re-emerged: 0.1965 seconds for the RF, 




Figure 9 – Swing of hemi-PD rats treated with BoNT-A 
Changes in swing after infusion of 0.5 ng of BoNT-A at the EPN (n=8 per group). Paws 
were measured individually (RF: right front, RH: right hind, LF: left front, and LH: left 
hind) and organized on the x-axis. Experimental timepoints are reflected according to the 
legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham lesioned) animals tested 
at week 0, and BoNT-A (or sham vehicle) animals tested at 1 week, 1 month or 3 months 
following treatment. Sham lesioned rats showed no changes in swing after vehicle (A) or 
BoNT-A injection (B). Vehicle injection did not reduce the increased swing of 6-OHDA 
lesioned rats (C). 0.5 ng of BoNT decreased the swing of 6-OHDA lesioned rats at 1 week 
and 1 month, but no effect was seen at 3 months (D). All results are presented as mean ± 
sem. Asterisks indicate significant changes compared to pre-lesioned animals (C) or 
lesioned animals (D) according to repeated measures one-way ANOVA and post hoc 








3.2.6  Changes in Step Cycle 
Step cycle (also referred to as stride), which is the duration between two consecutive 
contacts of the same paw, was measured by the CatWalk apparatus. Step cycle was not 
significantly affected by sham lesioning of the MFB (naïve vs timepoint 0 in Figure 10 A 
and B). Moreover, vehicle injection (Figure 10 A) or 0.5 ng of BoNT-A at the EPN (Figure 
10 B) in these sham lesioned control animals had no significant effect in step cycle in any 
of the paws across all experimental timepoints.  
Consistent with the changes seen in stand and swing, 6-OHDA lesioning of the MFB 
resulted in a significant increase in step cycle (naïve vs timepoint 0 in Figure 10 C and D). 
The step cycle across all paws increased from an average of 0.3539 seconds in naïve 
animals to 0.5868 seconds in 6-OHDA lesioned animals.  
In 6-OHDA lesioned animals, vehicle injection at the EPN had no effect on the elevated 
step cycle in all paws (Figure 10 C). Injection of 0.5 ng of BoNT-A at the EPN 
significantly reduced the step cycle across all paws of 6-OHDA lesioned animals (Figure 
10 D). At 1 week following BoNT-A infusion, step cycle significantly decreased to 
0.3494 seconds for the RF (F(1,8) = 9.739, p = 0.0025), 0.3448 seconds for the RH 
(F(1,8) = 14.28, p = 0.0009), 0.3540 seconds for the LF (F(1,11) = 12.65, p = 0.0023) and 
0.3421 seconds for the LH (F(1,9) = 15.07, p = 0.0002). At 1 month following BoNT-A 
injection, step cycle remained significantly reduced at 0.3623 seconds for the RF (F(1,8) 
= 9.739, p = 0.0008), 0.3471 seconds for the RH (F(1,8) = 14.28, p = 0.0003), 0.3450 
seconds for the LF (F(1,11) = 12.65, p = 0.0028) and 0.3507 seconds for the LH (F(1,9) = 
15.07, p = 0.0002). However, at 3 months following BoNT-A administration, the longer 
step cycle of lesioned animals re-emerged: 0.648 seconds for the RF, 0.6314 seconds for 





Figure 10 – Step cycle of hemi-PD rats treated with BoNT-A 
Changes in step cycle after injection of 0.5 ng of BoNT-A at the EPN (n=8 per group). 
Paws were measured individually (RF: right front, RH: right hind, LF: left front, and LH: 
left hind) and organized on the x-axis. Experimental timepoints are reflected according to 
the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham lesioned) animals 
tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 week, 1 month or 3 
months following treatment. Sham lesioned rats showed no changes in step cycle after 
vehicle (A) or BoNT-A injection (B). Vehicle injection did not reduce the increased step 
cycle of 6-OHDA lesioned rats (C). 0.5 ng of BoNT decreased the step cycle of 6-OHDA 
lesioned rats at 1 week and 1 month, but no effect was seen at 3 months (D). All results are 
presented as mean ± sem. Asterisks indicate significant changes compared to pre-lesioned 
animals (C) or lesioned animals (D) according to repeated measures one-way ANOVA and 







3.2.7  Changes in Duty Cycle 
The CatWalk apparatus was also used to detect changes in duty cycle, which is stand 
represented as a percentage of step cycle. No significant changes in duty cycle were 
detected following sham lesioning of the MFB (naïve vs timepoint 0 in Figure 11 A and 
B). Similarly, vehicle injection (Figure 11 A) or 0.5 ng of BoNT-A at the EPN (Figure 11 
B) in these sham lesioned control animals did not affect duty cycle of the paws. 
Along with the changes seen in stand and step cycle, 6-OHDA lesioning of the MFB lead 
to a significant increase in duty cycle (naïve vs timepoint 0 in Figure 11 C and D). Duty 
cycle across all paws increased from an average of 56.68 in naïve animals to 64.08% in 6-
OHDA lesioned animals.  
In these lesioned animals, vehicle injection at the EPN did not affect the increased duty 
cycle in any paw (Figure 11 C). On the contrary, infusion of 0.5 ng of BoNT-A at the 
EPN significantly decreased the duty across all paws of 6-OHDA lesioned animals 
(Figure 11 D). After 1 week of BoNT-A injection, duty cycle significantly returned to 
55.04% for the RF (F(2,19) = 8.601, p = 0.0045), 56.38% for the RH (F(1,12) = 8.028, p 
= 0.0041), 54.61% for the LF (F(1,12) = 7.771, p = 0.0075) and 58.95% for the LH 
(F(2,14) = 7.947, p = 0.0006). After 1 month, the reduced duty cycle persisted 
significantly at 55.99% for the RF (F(2,19) = 8.601, p = 0.0336), 59.57% for the RH 
(F(1,12) = 8.028, p = 0.0007), 54.76% for the LF (F(1,12) = 7.771, p = 0.0312) and 
59.66% for the LH (F(2,14) = 7.947, p = 0.0091).  However, after 3 months following 
BoNT-A injection, the duty cycle of parkinsonian animals increased to 64.52% for the 






Figure 11 – Duty cycle of hemi-PD rats treated with BoNT-A 
Changes in duty cycle after administration of 0.5 ng of BoNT-A at the EPN (n=8 per 
group). Paws were measured individually (RF: right front, RH: right hind, LF: left front, 
and LH: left hind) and organized on the x-axis. Experimental timepoints are reflected 
according to the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham 
lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 
week, 1 month or 3 months following treatment. Sham lesioned rats showed no changes in 
duty cycle after vehicle (A) or BoNT-A injection (B). Vehicle injection did not reduce the 
increased duty cycle of 6-OHDA lesioned rats (C). 0.5 ng of BoNT decreased the duty 
cycle of 6-OHDA lesioned rats at 1 week and 1 month, but no effect was seen at 3 months 
(D). All results are presented as mean ± sem. Asterisks indicate significant changes 
compared to pre-lesioned animals (C) or lesioned animals (D) according to repeated 








3.2.8  Changes in Single Stance 
Single stance, the duration of contact for a single paw when the contralateral paw is in 
swing, was also measured by the CatWalk apparatus. Sham lesioning of the MFB did not 
significantly affect single stance (naïve vs timepoint 0 in Figure 12 A and B). Likewise, 
single stance was unaffected by vehicle injection (Figure 12 A) or 0.5 ng of BoNT-A at the 
EPN (Figure 12 B) in these sham lesioned control animals. 
Consistent with other CatWalk studies involving parkinsonian rodents, 6-OHDA lesioning 
of the MFB resulted in a significant increase in single stance (naïve vs timepoint 0 in Figure 
12 C and D). Single stance across all paws increased from an average of 0.1422 seconds in 
naïve animals to 0.1955 seconds in 6-OHDA lesioned animals.  
In these 6-OHDA lesioned animals, vehicle injection at the EPN had no effect on the 
increased single stance in any paw (Figure 12 C). However, injection of 0.5 ng of BoNT-
A at the EPN significantly decreased the single stance across all paws of 6-OHDA lesioned 
animals (Figure 12 D). Following 1 week of BoNT-A injection, single stance significantly 
decreased to 0.1535 seconds for the RF (F(1,12) = 12.19, p = 0.0065), 0.1335 seconds for 
the RH (F(2,14) = 12.92, p = 0.0063), 0.1484 seconds for the LF (F(2,18) = 10.21, p = 
0.0005) and 0.1363 seconds for the LH (F(2,15) = 13.54, p = 0.0201). After 1 month, the 
reduced single stance remained significantly lower at 0.1533 seconds for the RF (F(1,12) 
= 12.19, p = 0.0004), 0.1254 seconds for the RH (F(2,14) = 12.92, p = 0.0052), 0.1488 
seconds for the LF (F(2,18) = 10.21, p = 0.0020) and 0.1296 seconds for the LH (F(2,15) 
= 13.54, p = 0.0050). However, 3 months following BoNT-A injection, the single stance 
of lesioned animals returned to 0.2126 seconds for the RF, 0.1680 seconds for the RH, 







Figure 12 – Single stance of hemi-PD rats treated with BoNT-A 
Changes in single stance after infusion of 0.5 ng of BoNT-A at the EPN (n=8 per group). 
Paws were measured individually (RF: right front, RH: right hind, LF: left front, and LH: 
left hind) and organized on the x-axis. Experimental timepoints are reflected according to 
the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham lesioned) animals 
tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 week, 1 month or 3 
months following treatment. Sham lesioned rats showed no changes in single stance after 
vehicle (A) or BoNT-A injection (B). Vehicle injection did not reduce the increased single 
stance of 6-OHDA lesioned rats (C). 0.5 ng of BoNT decreased the single stance of 6-
OHDA lesioned rats at 1 week and 1 month, but no effect was seen at 3 months (D). All 
results are presented as mean ± sem. Asterisks indicate significant changes compared to 
pre-lesioned animals (C) or lesioned animals (D) according to repeated measures one-way 







3.2.9  Changes in Initial Dual Stance 
The CatWalk apparatus was also used to detect initial dual stance, the duration of the first 
step in a step cycle of a paw that the contralateral paw also contacts the walkway. Sham 
lesioning of the MFB had no significant effect on initial dual stance (naïve vs timepoint 0 
in Figure 13 A and B). Furthermore, in these sham lesioned control animals, initial dual 
stance was neither affected by vehicle injection (Figure 13 A) or 0.5 ng of BoNT-A at the 
EPN (Figure 13 B).  
Following 6-OHDA lesioning of the MFB, a significant increase in initial dual stance was 
observed across all paws (naïve vs timepoint 0 in Figure 13 C and D). Initial dual stance 
across all paws increased from an average of 0.0358 seconds in naïve animals to 0.1072 
seconds in 6-OHDA lesioned animals.  
Subsequently, vehicle injection at the EPN of 6-OHDA lesioned animals had no effect on 
the increased initial dual stance in any paw (Figure 13 C). However, administration of 0.5 
ng of BoNT-A at the EPN significantly decreased the initial dual stance across all paws of 
6-OHDA lesioned animals (Figure 13 D). At 1 week following BoNT-A injection, initial 
dual stance significantly decreased to 0.0309 seconds for the RF (F(1,9) = 8.499, p = 
0.0337), 0.0380 seconds for the RH (F(1,9) = 7.302, p = 0.0268), 0.0185 seconds for the 
LF (F(1,7) = 1.952, p = 0.0035) and 0.0355 seconds for the LH (F(1,8) = 5.502, p = 0.0058). 
At 1 month, the shorter initial dual stance remained significantly lower at 0.0487 seconds 
for the RH (F(1,9) = 7.302, p = 0.0494), 0.0236 seconds for the LF (F(1,7) = 1.952, p = 
0.0103) and 0.0485 seconds for the LH (F(1,8) = 5.502, p = 0.0179), however was 
insignificant at 0.0414 seconds for the RF. At 3 months following BoNT-A injection, the 
initial dual stance of lesioned animals returned to 0.1139 seconds for the RF, 0.1585 





Figure 13 – Initial dual stance of hemi-PD rats treated with BoNT-A 
Changes in initial dual stance after administration of 0.5 ng of BoNT-A at the EPN (n=8 
per group). Paws were measured individually (RF: right front, RH: right hind, LF: left 
front, and LH: left hind) and organized on the x-axis. Experimental timepoints are reflected 
according to the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham 
lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 
week, 1 month or 3 months following treatment. Sham lesioned rats showed no changes in 
initial dual stance after vehicle (A) or BoNT-A injection (B). Vehicle injection did not 
reduce the increased initial dual stance of 6-OHDA lesioned rats (C). 0.5 ng of BoNT 
decreased the initial dual stance of 6-OHDA lesioned rats at 1 week and 1 month, but no 
effect was seen at 3 months (D). All results are presented as mean ± sem. Asterisks indicate 
significant changes compared to pre-lesioned animals (C) or lesioned animals (D) 







3.2.10  Changes in Terminal Dual Stance 
Terminal dual stance, the duration of the second step in a step cycle of a paw that the 
contralateral paw also contacts the walkway, was also measured by the CatWalk apparatus. 
No significant changes in terminal dual stance were detected following sham lesioning of 
the MFB (naïve vs timepoint 0 in Figure 14 A and B). Similarly, vehicle injection (Figure 
14 A) or 0.5 ng of BoNT-A at the EPN (Figure 14 B) in these sham lesioned control animals 
did not affect the terminal dual stance of the paws. 
Following 6-OHDA lesioning of the MFB, a significant increase in terminal dual stance 
was detected only in the left paws (naïve vs timepoint 0 in Figure 14 C and D). Terminal 
dual stance of the LF increased from 0.0256 seconds in naïve animals to 0.1164 seconds in 
6-OHDA lesioned animals, and from 0.0440 seconds to 0.1356 seconds for the LH. 
Although an increase in terminal dual stance was observed in the right paws, it was not 
significant.  
In 6-OHDA lesioned animals, vehicle injection at the EPN had no effect on the increased 
terminal dual stance of the left paws (Figure 14 C). However, injection of 0.5 ng of BoNT-
A at the EPN significantly decreased the terminal dual stance in the left paws of 6-OHDA 
lesioned animals (Figure 14 D). At 1 week post-BoNT-A injection, terminal dual stance 
significantly decreased to 0.0288 seconds for the LF (F(1,10) = 11.31, p = 0.0057) and to 
0.0381 seconds for the LH (F(1,7) = 8.025, p = 0.0011). At 1 month post-BoNT-A, terminal 
dual stance remained significantly decreased at 0.0345 seconds for the LF (F(1,10) = 11.31, 
p = 0.0181) and 0.0493 seconds for the LH (F(1,7) = 8.025, p = 0.0049). However, at 3 
months post-BoNT-A injection, the terminal dual stance of lesioned animals increased to 





Figure 14 – Terminal dual stance of hemi-PD rats treated with BoNT-A 
Changes in terminal dual stance after injection of 0.5 ng of BoNT-A at the EPN (n=8 per 
group). Paws were measured individually (RF: right front, RH: right hind, LF: left front, 
and LH: left hind) and organized on the x-axis. Experimental timepoints are reflected 
according to the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham 
lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 
week, 1 month or 3 months following treatment. Sham lesioned rats showed no changes in 
terminal dual stance after vehicle (A) or BoNT-A injection (B). Vehicle injection did not 
reduce the increased terminal dual stance in the left paws of 6-OHDA lesioned rats (C). 0.5 
ng of BoNT decreased the terminal dual stance in the left paws of 6-OHDA lesioned rats 
at 1 week and 1 month, but no effect was seen at 3 months (D). All results are presented as 
mean ± sem. Asterisks indicate significant changes compared to pre-lesioned animals (C) 
or lesioned animals (D) according to repeated measures one-way ANOVA and post hoc 






3.2.11  Changes in Swing Speed 
The CatWalk apparatus was also used to detect the swing speed across all paws. Sham 
lesioning of the MFB did not significantly affect the swing speed of animals in any of their 
paws (naïve vs timepoint 0 in Figure 15 A and B). Additionally, in these control animals, 
vehicle injection (Figure 15 A) or 0.5 ng of BoNT-A at the EPN (Figure 15 B) did not 
significantly alter swing speed in any of the paws across all experimental timepoints.  
Swing speed significantly decreased following 6-OHDA lesioning of the MFB (naïve vs 
timepoint 0 in Figure 15 C and D). The average swing speed across all paws reduced from 
148.8 cm/seconds in naïve animals to 114.8 cm/seconds in 6-OHDA lesioned animals.  
In these 6-OHDA lesioned animals, vehicle injection at the EPN had no significant effects 
on swing speed in any paw (Figure 15 C). Infusion of 0.5 ng of BoNT-A at the EPN 
significantly increased the swing speed across all paws of 6-OHDA lesioned animals 
(Figure 15 D). At 1 week after BoNT-A administration, swing speed significantly increased 
to 159.0 cm/seconds for the RF (F(2,18) = 18.47, p = 0.0001), 169.2 cm/seconds for the 
RH (F(2,16) = 20.89, p = 0.0003), 153.4 cm/seconds for the LF (F(2,17) = 10.29, p = 
0.0037) and 174.6 cm/seconds for the LH (F(2,18) = 30.24, p = 0.0008). At 1 month after 
BoNT-A injection, swing speed remained significantly elevated at 163.0 cm/seconds for 
the RF (F(2,18) = 18.47, p = 0.0022), 181.3 cm/seconds for the RH (F(2,16) = 20.89, p = 
0.0023), 161.9 cm/seconds for the LF (F(2,17) = 10.29, p = 0.0010) and 186.6 cm/seconds 
for the LH (F(2,18) = 30.24, p = 0.0008). However, at 3 months after BoNT-A infusion, 
lesioned animals returned to a slower swing speed, 118.7 cm/seconds for the RF, 121.5 





Figure 15 – Swing speed of hemi-PD rats treated with BoNT-A 
Changes in swing speed after infusion of 0.5 ng of BoNT-A at the EPN (n=8 per group). 
Paws were measured individually (RF: right front, RH: right hind, LF: left front, and LH: 
left hind) and organized on the x-axis. Experimental timepoints are reflected according to 
the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham lesioned) animals 
tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 week, 1 month or 3 
months following treatment. Sham lesioned rats showed no changes in swing speed after 
vehicle (A) or BoNT-A injection (B). Vehicle injection did not improve the reduced swing 
speed of 6-OHDA lesioned rats (C). 0.5 ng of BoNT increased the swing speed of 6-OHDA 
lesioned rats at 1 week and 1 month, but no effect was seen at 3 months (D). All results are 
presented as mean ± sem. Asterisks indicate significant changes compared to pre-lesioned 
animals (C) or lesioned animals (D) according to repeated measures one-way ANOVA and 








3.2.12  Changes in Stride Length 
The stride length, the distance between two consecutive placements of the same paw, was 
also measured by the CatWalk apparatus. Stride length was not significantly affected by 
sham lesioning of the MFB (naïve vs timepoint 0 in Figure 16 A and B). Furthermore, 
following vehicle injection (Figure 16 A) or 0.5 ng of BoNT-A (Figure 16 B) at the EPN, 
no changes in stride length were detected in any of the paws of sham lesioned animals.  
6-OHDA lesioning of the MFB resulted in a slight reduction in stride length but no 
significance was detected (naïve vs timepoint 0 in Figure 16 C and D). The average stride 
length across all paws decreased insignificantly from 22.03 cm in naïve animals to 20.70 
cm in 6-OHDA lesioned animals.  
Subsequently, vehicle injection at the EPN of 6-OHDA lesioned animals did not alter stride 
length (Figure 16 C). However, injection of 0.5 ng of BoNT-A at the EPN significantly 
increased the stride length 6-OHDA lesioned animals (Figure 16 D). This change was 
present at different time points for specific paws (Figure 16 D). At 1 week following BoNT-
A administration, stride length significantly increased to 23.89 cm for the RF (F(2,17) = 
7.945, p = 0.0071), 23.50 cm for the RH (F(2,19) = 11.35, p = 0.0003), but no significant 
changes were detected in either left paws. At 1 month after BoNT-A injection, stride length 
significantly increased across all paws, to 24.60 cm for the RF (F(2,17) = 7.945, p = 
0.0009), 23.97 cm for the RH (F(2,19) = 11.35, p = 0.0085), 23.73 cm for the LF (F(2,19) 
= 6.179, p = 0.0259) and 23.99 cm for the LH (F(2,18) = 5.42, p = 0.0261). However, at 3 
months after BoNT-A infusion, stride length decreased in lesioned animals to 21.51 cm for 





Figure 16 – Stride length of hemi-PD rats treated with BoNT-A 
Changes in stride length after administration of 0.5 ng of BoNT-A at the EPN (n=8 per 
group). Paws were measured individually (RF: right front, RH: right hind, LF: left front, 
and LH: left hind) and organized on the x-axis. Experimental timepoints are reflected 
according to the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham 
lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 
week, 1 month or 3 months following treatment. Sham lesioned rats showed no changes in 
stride length after vehicle (A) or BoNT-A injection (B). 6-OHDA lesioning of the MFB 
did not significantly alter stride length (C and D). Vehicle injection had no effect on stride 
length of 6-OHDA lesioned rats (C). 0.5 ng of BoNT increased the stride length of 6-
OHDA lesioned rats in the right paws at 1 week and in all paws at 1 month (D). All results 
are presented as mean ± sem. Asterisks indicate significant changes compared to pre-
lesioned animals (C) or lesioned animals (D) according to repeated measures one-way 







3.2.13  Changes in Max Contact Area 
The max contact area of each paw was also measured by the CatWalk apparatus. As 
expected, max contact area was unaffected by sham lesioning of the MFB (naïve vs 
timepoint 0 in Figure 17 A and B). Subsequently, in these control animals, vehicle injection 
(Figure 17 A) or 0.5 ng of BoNT-A at the EPN (Figure 17 B) did not significantly affect 
the max contact area of any of the paws across all experimental timepoints.  
Consistent with findings from other CatWalk studies involving parkinsonian rodents, 6-
OHDA lesioning of the MFB resulted in an asymmetric reduction of max contact area in 
only the left paws (naïve vs timepoint 0 in Figure 17 C and D). The max contact area of 
the LF decreased from 2.592 cm2 in naïve animals to 1.620 cm2 in 6-OHDA lesioned 
animals, and from 2.084 cm2 to 1.315 cm2 in the LH. No significant reduction in max 
contact area was detected in the right paws of 6-OHDA lesioned animals.  
Subsequently, in 6-OHDA lesioned animals, vehicle injection at the EPN had no significant 
effects on max contact area (Figure 17 C). Administration of 0.5 ng of BoNT-A at the EPN 
also had no significant effect on max contact area in either affected (left) or unaffected 
(right) paws of 6-OHDA lesioned animals (Figure 17 D). No changes were detected at any 




Figure 17 – Max contact area of hemi-PD rats treated with BoNT-A 
Changes in max contact area after infusion of 0.5 ng of BoNT-A at the EPN (n=8 per 
group). Paws were measured individually (RF: right front, RH: right hind, LF: left front, 
and LH: left hind) and organized on the x-axis. Experimental timepoints are reflected 
according to the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham 
lesioned) animals tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 
week, 1 month or 3 months following treatment. Sham lesioned rats showed no changes in 
max contact area after vehicle (A) or BoNT-A injection (B). 6-OHDA lesioning of the 
MFB significantly reduced max contact area of left paws (C and D). 6-OHDA lesioned rats 
showed no improvements in max contact area after vehicle (C) or BoNT-A injection (D). 
All results are presented as mean ± sem. Asterisks indicate significant changes compared 
to pre-lesioned animals (C) or lesioned animals (D) according to repeated measures one-













3.2.14  Changes in Mean Intensity 
Lastly, the CatWalk apparatus was used to detect the mean intensity of all paws. Sham 
lesioning of the MFB did not significantly affect the mean intensity of animals in any of 
their paws (naïve vs timepoint 0 in Figure 18 A and B). In these control animals, vehicle 
injection (Figure 18 A) or 0.5 ng of BoNT-A at the EPN (Figure 18 B) did not significantly 
affect the mean intensity of any of the paws across all experimental timepoints.  
Similar to the results of max contact area, 6-OHDA lesioning of the MFB resulted in an 
asymmetric reduction of mean intensity in only left paws (naïve vs timepoint 0 in Figure 
18 C and D). The mean intensity of the LF decreased from 83.18 in naïve animals to 59.35 
in 6-OHDA lesioned animals, and from 79.84 to 57.15 in the LH. No significant changes 
in mean intensity was detected in the right paws of 6-OHDA lesioned animals. 
In these hemiparkinsonian animals, vehicle injection at the EPN had no significant effects 
on mean intensity (Figure 18 C). Infusion of 0.5 ng of BoNT-A at the EPN also had no 
significant effect on mean intensity in either affected (left) or unaffected (right) paws of 6-
OHDA lesioned animals (Figure 17 D). No significant changes were observed at any of 





Figure 18 – Mean intensity of hemi-PD rats treated with BoNT-A 
Changes in mean intensity after injection of 0.5 ng of BoNT-A at the EPN (n=8 per group). 
Paws were measured individually (RF: right front, RH: right hind, LF: left front, and LH: 
left hind) and organized on the x-axis. Experimental timepoints are reflected according to 
the legend: naïve rats tested prior to any surgeries, 6-OHDA (or sham lesioned) animals 
tested at week 0, and BoNT-A (or sham vehicle) animals tested at 1 week, 1 month or 3 
months following treatment. Sham lesioned rats showed no changes in mean intensity after 
vehicle (A) or BoNT-A injection (B). 6-OHDA lesioning of the MFB significantly reduced 
mean intensity of left paws (C and D). 6-OHDA lesioned rats showed no improvements in 
mean intensity after vehicle (C) or BoNT-A injection (D). All results are presented as mean 
± sem. Asterisks indicate significant changes compared to pre-lesioned animals (C) or 
lesioned animals (D) according to repeated measures one-way ANOVA and post hoc 













3.2.15  Changes in Walking Pattern 
Overall, all the aforementioned quantitative gait parameters can be reflected in the walking 
pattern of experimental animals (Figure 19). Naïve untreated animals traversed the 
walkway with short consistent steps (Figure 19 A). Following 6-OHDA lesioning, animals 
walked at an irregular pace with fewer steps per second, cumulating in a longer time to 
traverse the walkway (Figure 19 B). The walking pattern of lesioned animals returned to 
normal (consistent repetitive short steps) after administration of BoNT-A at 1 week and 1 
month (Figure 19 C and D). An irregular walking pattern consisting of long uneven steps 




Figure 19 – Walking pattern of hemi-PD rats treated with BoNT-A 
Walking pattern and individual paws (RF: right front, RH: right hind, LF: left front, and 
LH: left hind) were measured at given experimental timepoints on the y-axis. Normal 
walking pattern of naïve untreated animals (A). 6-OHDA lesioned animals crossed the 
walkway at a slower irregular pace (B). Following BoNT-A infusion, walking pattern of 
animals appeared normal at 1 week (C) and 1 month (D), but abnormalities re-emerged at 







3.2.16 Summary of CatWalk Results 
The gait changes induced by 6-OHDA lesioning and subsequent 1-month post BoNT-A 
injection at the EPN is summarized in Table 3.   













Effect of 6-OHDA 
Lesioning 
Effect of BoNT-A 
Treatment at 1 month 
Average Speed (cm/s) ↓ ↑ 
Body Speed Variation (%) ↑ ↓ 
Cadence (steps/s) ↓ ↑ 
Duty Cycle (%) ↑ ↓ 
Initial Dual Stance (s) ↑ ↓ 
Max Contact Area (cm2) ↓ (left only) n.s. 
Mean Intensity ↓ (left only) n.s. 
Single Stance (s) ↑ ↓ 
Stand (s) ↑ ↓ 
Step Cycle (s) ↑ ↓ 
Stride Length (cm) n.s. ↑ 
Swing Speed (cm/s) ↓ ↑ 
Terminal Dual Stance (s) ↑ (left only) ↓ (left only) 
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3.3 Results of Immunohistochemical Staining 
3.3.1  Verification of 6-OHDA Lesion  
Unilateral 6-OHDA lesioning of the MFB was verified post-mortem in all animals by 
significant reduction of TH-positive terminals in the striatum (Figure 20 A) and TH-
positive cell bodies in the SNpc (Figure 20 B) on the injected right side.  
 
 
Figure 20 – 6-OHDA lesioning of the MFB 
6-OHDA lesioning of the right MFB results in reduction in TH immunoreactivity in the 
ipsilateral striatum (A) and the substantia nigra (B). Presence of TH was detected in the 









3.3.2  BoNT-A Selectively Targets Glutamatergic Terminals   
Immunofluorescent labelling of synaptophysin was used to identify the density of all types 
of synaptic terminals, vesicular glutamate transporter 2 (vGluT2) was used to identify 
glutamatergic terminals, while glutamate decarboxylase 67 kDa (GAD67) was used for 
GABAergic terminals.  
6-OHDA lesioning of the MFB had no significant effect on the immunoreactivity of 
synaptophysin (Figure 21 A versus C), vGluT2 (Figure 21 F versus H) or GAD67 (Figure 
21 K versus M) at the EPN. Likewise, injection of 0.5 ng of BoNT-A at the EPN had no 
significant effect on any markers in control animals (Figure 21 B, G and L). However, 
administration of 0.5 ng of BoNT-A at the EPN significantly reduced the synaptophysin 
immunoreactivity at the EPN of 6-OHDA lesioned animals (Figure 21 D). The mean 
intensity of synaptophysin labelling decreased from 21.62 to 4.077 following BoNT-A 
administration at 1 month in 6-OHDA lesioned animals (H = 19.52, p = 0.0009) (Figure 
21 E). A corresponding decrease of vGluT2 was detected at the EPN following BoNT-A 
administration in lesioned animals (Figure 21 I). The mean intensity of vGluT2 reduced 
from 8.906 to 2.112 at 1 month post-infusion of 0.5 ng of BoNT-A in lesioned animals (H 
= 22.48, p = 0.0007) (Figure 21 J). However, no significant changes in GAD67 staining 




Figure 21 – Immunostaining of synaptic markers at the EPN 
Immunolabelling at the EPN of synaptophysin (A-D), vGluT2 (F-I) and GAD67 (K-N) of 
control animals treated with vehicle (first column), control animals treated with BoNT-A 
(second column), lesioned animals treated with vehicle (third column) and lesioned 
animals treated with BoNT-A at 1 month (fourth column). Reduction in synaptophysin and 
vGluT2 were detected at the EPN at 1 month following BoNT-A administration in 6-
OHDA lesioned animals. No change in GAD67 immunostaining was detected after BoNT-
A injection. Mean intensity (last column) was measured for each image, where each dot 
represents a processed section (n=9). All results are presented as mean ± sem. Asterisks 
indicate significant changes between groups according to Kruskal-Wallis test and post hoc 














3.3.3  Effects of BoNT-A Injection are Non-Permanent 
Administration of 0.5 ng of BoNT-A at the EPN of lesioned animals significantly reduced 
the synaptophysin immunoreactivity at the EPN as early as 1 week post-injection (Figure 
22 A). This reduction in synaptophysin labelling persisted at 1 month post-infusion (Figure 
22 B). However, at 3 months post-injection, synaptophysin levels increased (Figure 22 C). 
The mean intensity of synaptophysin labelling was 5.75 at 1 week (H = 16.95, p = 0.0077), 
4.08 at 1 month (H = 16.95, p = 0.0002), compared to 17.61 at 3 months (Figure 22 D).  
Correspondingly, infusion of BoNT-A at the EPN of lesioned animals significantly 
decreased the immunoreactivity of vGluT2 at the EPN at 1 week post-injection (Figure 22 
E). At 1 month post-administration, the level of vGluT2 labelling continued to decrease 
(Figure 22 F). However, at 3 months post-injection, vGluT2 immunoreactivity increased 
(Figure 22 G). The mean intensity of vGluT2 labelling was 4.77 at 1 week (H = 17.36, p = 
0.0320), 2.112 at 1 month (H = 17.36, p = 0.0001), compared to 10.54 at 3 months (Figure 
22 H).  
On the contrary, injection of BoNT-A at the EPN had no significant effects on GAD67 
immunolabelling at any of the tested experimental timepoints (Figure 22 I, J and K). The 
mean intensity of GAD67 labelling remained consistently insignificant at 11.73 at 1 week, 






Figure 22 – Effect of BoNT-A on synaptic markers at various timepoints  
Immunolabelling at the EPN of synaptophysin (A-C), vGluT2 (E-G) and GAD67 (I-K) of 
6-OHDA lesioned animals injected with BoNT-A at 1 week (first column), 1 month 
(second column) and 3 months (third column). Reduction in synaptophysin and vGluT2 
were detected at the EPN at 1 week and 1 month following BoNT-A administration in 6-
OHDA lesioned animals. No change in GAD67 immunostaining was detected after BoNT-
A injection. Mean intensity (last column) was measured for each image, where each dot 
represents a processed section (n=9). All results are presented as mean ± sem. Asterisks 
indicate significant changes between groups according to Kruskal-Wallis test and post hoc 











3.3.4  BoNT-A Infusion Elicits a Small Immune Response  
Immunofluorescent labelling of glial fibrillary acidic protein (GFAP) was used as an 
astrocyte marker to detect inflammation. Vehicle injection at the EPN of 6-OHDA lesioned 
animals resulted in detectable levels of GFAP at the EPN (Figure 23 A and B). Moreover, 
infusion of 0.5 ng of BoNT-A at the EPN of lesioned animals lead to a pronounced 
upregulation of GFAP expression, proliferation and overlap (Figure 23 C and D). 
Specifically, the mean intensity of GFAP immunoreactivity significantly increased from 
10.58 in vehicle treated animals to 14.25 in BoNT-A infused animals (p = 0.0025) (Figure 







Figure 23 – GFAP expression in lesioned animals treated with BoNT-A or vehicle  
Immunolabelling of GFAP at the EPN of 6-OHDA lesioned animals injected with vehicle 
(A/B) or BoNT-A (C/D). Detectable levels of GFAP were present following vehicle 
injection at the EPN. Upregulation of GFAP expression was observed at 1 month following 
0.5 ng of BoNT-A infusion in 6-OHDA lesioned animals. First column displays lower 
magnification (20x) and second column displays higher magnification (63x). Mean 
intensity (E) was measured for each lower magnification image, where each dot represents 
a processed section (n=9). All results are presented as mean ± sem. Asterisks indicate 
significant changes between groups according to an unpaired Student’s t-test. **p<0.01 
Scale bar: 50 m  
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Chapter 4  
4 Discussion 
4.1 Safety of Central BoNT-A Injection 
In recent years, numerous studies have reported on the safety and viability of direct 
injections of BoNT in the central nervous system of various rodent models of neurological 
diseases, including PD and epilepsy (Hawlitschka et al., 2013; Mazzocchio & Caleo, 2015; 
Chaddock et al., 2004; Wree et al., 2010). Due to its well-established mechanism of action 
to deplete acetylcholine exocytosis, intrastriatal injections of BoNT-A have been 
administered to improve motor deficits in PD rodent models (Wree et al., 2010; Antipova 
et al., 2013; Mehlan et al., 2016). Consistent with the findings of these previous studies 
involving the striatum, our results demonstrate that central administration of BoNT-A at 
the EPN is also safe. No mortality of any experimental animals was seen following 
infusions of either 0.05 ng or 0.5 ng of BoNT-A into the EPN. However, contrary to 
Antipova et al. (2013) in which no changes in GFAP immunostaining at the striatum was 
seen between untreated controls and BoNT-A treated animals, an increase in GFAP activity 
was detected following BoNT-A injection at the EPN. This upregulation of GFAP 
expression suggests that BoNT-A does induce inflammation leading to gliosis in the EPN.    
In addition to the viability and safety of central BoNT-A injections, our results demonstrate 
that both behavioural and molecular effects induced by BoNT-A are transient. At 3 months 
post-BoNT-A infusion, the mobility of 6-OHDA lesioned rodents, as assessed by the 
CatWalk apparatus, returned to levels consistent with pre-injection (i.e. return of 
parkinsonian motor impairments). The re-emergence of pathological apomorphine-induced 
rotations at 3 months also demonstrate that BoNT-A effects are only transient and does not 
induce permanent changes within the BG. Moreover, based on our immunohistochemical 
findings, the reduction of synaptophysin and vGluT2 at the EPN was transient, as the 
density of these synaptic markers increased following 3 months post-injection. This 
reversal of both behavioural and molecular effects at approximately 3 months follows a 
similar timeline of treatment waning and physiological recovery involving injections in 
peripheral targets in a clinical setting (Kim et al., 2014; Samotus et al., 2016; Zakin & 
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Simpson, 2017). As a clinical therapeutic for tremor, the time of peak BoNT-A effect is 
typically observed at 4 weeks post-injection, with repeat injections occurring every 3-4 
months. Thus, the central effects of BoNT-A observed in our study reflects a very similar 
timeline to its well-established peripheral use.  
Overall, our study demonstrated a safe and transient effect of BoNT-A in the central 
nervous system to alleviate motor impairments in a rodent PD model. 
 
4.2 Selectivity of Central BoNT-A Injection 
In addition to its ability to inhibit acetylcholine release, there is clear evidence that BoNT-
A also affects other excitatory neurotransmitter exocytosis including glutamate (Sanchez-
Prieto et al., 1987; Bigalke et al., 1981; Ashton & Dolly, 1988; McMahon et al., 1992). 
Although these studies have reported on the ability of BoNT-A to suppress glutamate 
release, this work has been predominantly studied in vitro with the use of synaptosomes or 
cultured neurons. Moreover, injection of another BoNT subtype, BoNT-E has been used in 
vivo to supress glutamate hyperactivity in the central nervous system of a mouse model of 
epilepsy (Antonucci et al., 2008). However, at present, no study has yet to directly 
investigate the use of BoNT-A in the brain to inhibit glutamate neuroexocytosis in an 
animal model. Our study directly investigated the effect of intracerebral botulinum 
neurotoxin A to selectively block glutamate neurotransmission in an animal model and its 
physiological application to produce a sufficient and quantifiable behavioural outcome. 
The selectivity of BoNT-A on specific neuronal types was observed by 
immunofluorescence labelling of select biomarkers. Our results support the findings of in 
vitro studies that demonstrated a preference of BoNT-A on excitatory versus inhibitory 
synapses. This clear bias was demonstrated by the significant reduction in glutamatergic 
synaptic density marked by vGluT2 and lack of significant effect on GABAergic synapses 
identified by GAD67 at the EPN of BoNT-A treated lesioned animals. In the study by 
Sanchez-Prieto et al. (1987), this preference of BoNT-A on glutamatergic terminals 
developed approximately 2 hours following administration in cultured cortical 
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synaptosomes. In this study, this preferential action of BoNT-A appeared at the earliest 
tested experimental timepoint (1 week) and dissipated by the last experimental timepoint 
(3 months). From our results, the effect of BoNT-A on vGluT-2 labelled neurons was more 
effective at 1 month compared to 1 week, indicating a gradual and continuous effect.  
A study by Cai et al. (2017) explored the colocalization of BoNT-A with different 
biomarkers of motor neurons, neighbouring neurons, nerve fibers or glial cells at the spinal 
cord following intramuscular injections of BoNT-A. In contrast to the findings observed in 
our study, the authors did not report any effect of BoNT-A on glutamatergic neurons due 
to a lack of colocalization of cleaved SNAP-25 with glutamatergic neurons. However, 
these discrepancies may be attributed to differences in experimental technique and 
objectives. The study by Cai et al. was looking for a secondary effect on glutamatergic 
neurons at the spinal cord after retrograde transport from a peripheral muscle injection of 
BoNT-A. In contrast, our research project investigated a direct effect of BoNT-A on 
glutamatergic terminals at the site of central injection at the EPN. Furthermore, the study 
by Cai et al. utilized an antibody for cleaved SNAP-25 (the established target of BoNT-A) 
in order to visualize co-localization between cleaved SNAP-25 and various neuronal 
biomarkers, including vGluT2 for glutamatergic neurons. The authors failed to see co-
localization of cleaved SNAP-25 with any biomarkers for glutamatergic, GABAergic or 
catecholaminergic synaptic contacts. Surprisingly, the authors also did not report any co-
localization of cleaved SNAP-25 with even cholinergic neurons using 2D confocal 
techniques, but was able to observe co-localization with 3D reconstruction. Thus, based on 
the methods and objectives of this study, it is not unexpected that BoNT-A had no effect 
on glutamatergic terminals. It is important to note that in our study, no co-localization 
analysis was performed with vGluT2 and cleaved SNAP-25 as the commercial available 
antibody for cleaved SNAP-25 failed to demonstrated specificity (data not shown). This 
limitation is expanded in more detail in Chapter 4.6.2.  
Thus, our study is the first to report a significant histological effect by BoNT-A on 




4.3 Changes in Basal Ganglia Circuitry Following BoNT-A: 
Rotational Behaviour  
In experimental models of PD for preclinical research, it is well-established that unilateral 
injection of 6-OHDA into the MFB results in near total depletion of dopamine in the 
ipsilateral striatum. Within the denervated striatum, supersensitivity occurs in the 
remaining neurons, in which there is an upregulation of D1 and D2 postsynaptic receptors 
(Perese et al., 1989). Thus, when unilaterally lesioned animals are challenged with 
apomorphine, there is greater dopamine activity on the lesioned nigrostriatal projections 
(Ungerstedt, 1971; Deumens et al., 2002). In the ipsilateral BG network, the supersensitive 
excitatory D1 activity contributes to increased inhibition from the striatum to the GPi 
through the direct pathway and thus, less inhibition on thalamocortical centres. The 
supersensitive inhibitory D2 receptors results in less inhibition from the striatum to the GPe 
through the indirect pathway and thus, more inhibition on the STN. Thus, the supressed 
excitatory activity of the STN onto the GPi results in less inhibitory activity of the GPi to 
thalamocortical centres. The net alterations in BG circuitry all contribute to increased 
cortical activity ipsilateral to the lesion and thus, contralateral rotations away from the 
lesioned side. 
From our results, selective inhibition of glutamatergic input from the STN to EPN by 
BoNT-A significantly abolishes this apomorphine-induced rotational behaviour. Since the 
only intervention administered was the injection of BoNT-A within the EPN, the reduction 
of pathological rotations can be related to the established effect of BoNT-A, which is the 
suppression of incoming signals to the EPN. However, based on the aforementioned 
changes in BG circuitry in relationship to the supersensitive dopamine receptions and 
consequent contralateral apomorphine-induced rotations, it would be expected that 
suppression of STN excitatory activity to the GPi would fail to supress the pathological 
rotational behaviour of 6-OHDA lesioned animals and could even worsen apomorphine-
induced rotations, which is opposite to the outcome observed in our study. Thus, the 
observed abolishment of pathological rotations in BoNT-A injected animals may be due to 
secondary effects of BoNT-A, such as retrograde transport of BoNT-A from STN terminals 
to incoming cortical afferents, ultimately resulting in suppression of motor cortical activity. 
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Similarly, BoNT-A could be mediating effects that alter the firing pattern of glutamatergic 
STN terminals, which could result in re-organization of BG activity that consequently leads 
to reduction of pathological rotations. This proposed electrophysiological change will be 
further discussed as a future direction in Chapter 4.6.3.  
 
4.4 Changes in Basal Ganglia Circuitry Following BoNT-A: 
Locomotion  
It is well-established that loss of dopamine in PD results in changes of BG circuitry 
including an increase of STN activity on the GPi (Figure 24 A). This re-arrangement of the 
BG network leads to a reduction of thalamocortical activity and is therefore, linked to 
parkinsonian motor symptoms including gait impairments (Takakusaki, 2017). Thus, this 
study hypothesized that suppression of STN overactivity could lead to a re-balancing of 
BG circuitry to consequently improve motor impairments. From the data acquired by the 
CatWalk apparatus, hemiparkinsonian animals displayed an overall improvement in gait at 
1 week and 1 month following BoNT-A injection. Overall, 6-OHDA lesioned animals 
traversed the walkway with a more consistent and rapid pace. The specific changes seen 
for each gait parameter and their functional neuroanatomy significance for gait control are 
discussed in Chapter 4.5.5. However, here we address the general changes in BG circuitry 
following BoNT-A injection that could lead to overall improvements in locomotion.  
Unlike any previous CatWalk studies involving parkinsonian animals that observed 
improvements in gait following a specific intervention, this is the first study in which the 
connectivity between the STN-EPN was directly targeted and investigated. A study by 
Chuang et al. (2010), in which the CatWalk system was used, demonstrated that engrafting 
dopaminergic neurons derived from embryonic stem cells into the ipsilateral striatum of 
lesioned animals significantly improved their walking pattern and swing speed. Similarly, 
a study by Westin et al. (2012) reported that a single dose of levodopa mixed with 
Benserazide (a peripheral dopamine decarboxylase inhibitor) significantly improved 
numerous gait parameters (including stride length, swing speed, stand and step cycle) in a 
bilateral 6-OHDA model. However, our study focused on an intervention within the STN-
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EPN, and not at the striatum. There is clear evidence that modulation at these sites are 
already promising with surgical interventions in PD patients, such as lesioning and DBS, 
to alleviate motor impairments (Benabid et al., 1987; Deep-Brain Stimulation for 
Parkinson's Disease Study Group, 2001). 
By utilizing the ability of BoNT-A to block glutamate release from the STN, there is 
decreased excitatory outflow to the output nucleus of the BG, the GPi/EPN (Figure 24 B). 
This reduced activation of the EPN results in less inhibition to the ventral anterior and 
ventral lateral thalamic nuclei, which in turn stimulate the motor cortex to facilitate 
movement. In this paradigm, the loss of dopamine is not replenished or directly modulated, 
nor is the direct pathway affected by BoNT-A. The recovery of impaired mobility observed 
in the study offers support that despite a significant dopaminergic lesion, gait function can 
be significantly restored. Thus, blockade of STN activity by BoNT-A leads to sufficient 




Figure 24 – BG circuitry in parkinsonian states following BoNT-A injection  
Schematic diagram of the direct and indirect pathways of the BG circuitry in parkinsonian 
states without intervention (A) and with BoNT-A injection (B). Black arrows represent 
excitatory projections and grey arrows represent inhibitory projections. The thickness of 
the arrows indicates changes in activity of specific connections.  
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4.5 Effect of BoNT-A on Specific Gait Parameters 
4.5.1 Changes in Gait Parameters Following 6-OHDA Lesioning  
Numerous CatWalk studies have reported that following 6-OHDA lesioning of the MFB, 
animals display changes in both dynamic and static gait parameters (previously outlined in 
detail in Chapter 1.4.3). Amongst these gait parameters, an increase in stand and swing 
time were reported, which authors suggest reflected a reduction in average speed and 
cadence (Westin et al., 2012; Zhou et al., 2015). However, no study has yet to directly 
quantitively measure these impairments in speed, variation and cadence of the 6-OHDA 
PD model. This study directly assessed these parameters and observed that 6-OHDA 
lesioned animals reduced their speed and cadence and increased their body speed variation. 
This slower and irregular gait is thought to be reflective of an increase in rigidity and 
bradykinesia. Such differences are seen in clinical manifestations of PD symptoms such as 
reduced arm swing (Sofuwa et al., 2005; Jankovic, 2008).  
Moreover, the changes in static gait parameters (i.e. features independent on time) 
following 6-OHDA lesioning reported in this study were relatively consistent to findings 
described by other CatWalk studies (Chuang et al., 2010; Zhou et al., 2015). Significant 
reductions in max contact area and mean intensity were only seen in the left paws. This 
asymmetric presentation in the affected side is due to the unilateral depletion of dopamine 
in the contralateral hemisphere. It is likely that this asymmetry is emphasized by 
compensation in the unaffected right limbs. These gait disturbances in static parameters are 
most closely linked to an increase in rigidity and altered use of paw surface. However, not 
all static gait features displayed this asymmetric presentation and/or were affected by 6-
OHDA lesioning of the MFB. Although hemi-PD rodents in our study displayed a minor 
reduction in stride length across all limbs, no significance was detected. This is different 
than data directly reported by Zhou et al. (2015) in which stride length was significantly 
reduced in PD animals, as well as patients with PD who presented with a decreased stride 
length observed by Sofuwa et al. (2005).  
Similarly, the disturbances in dynamic gait parameters (i.e. features dependent on time) 
following 6-OHDA lesioning described in this study were comparable to findings reported 
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by other CatWalk studies (Chuang et al., 2010; Zhou et al., 2015). Increases in stand, swing, 
step cycle, duty cycle, single stance and initial dual stance were observed across all paws. 
These dynamic impairments are thought to model bradykinesia seen clinically in PD 
patients. A significant reduction in swing speed of lesioned animals is also thought to be 
reflective of an increase in muscle rigidity and bradykinesia, as well as a difficulty in the 
initiation of movements. This difficulty in initiation of movements after 6-OHDA lesioning 
has been reported by various studies that did not utilize the CatWalk apparatus (Olsson, 
Nikkhah, Bentlage, & Bjorklund, 1995; Metz, Tse, Ballermann, Smith, & Fouad, 2005; 
Shi, Luo, Woodward, & Chang, 2006). Furthermore, amongst these dynamic gait 
parameters, an asymmetrical increase in terminal dual stance of the left paws was observed 
in PD rodents. It is postulated that terminal dual stance is the most important parameter in 
mimicking delays by freezing of gait and postural instability (Dibble et al., 2004; Zhou et 
al., 2015). Disturbances in terminal dual stance in the 6-OHDA lesioned model also reflects 
a longer double limb support time in PD patients (Ebersbach et al., 1999).  
Overall, this study contributes to the current literature that unilateral 6-OHDA lesioning of 
the MFB induces numerous impairments in both static and dynamic gait parameters, which 
are assessed by the CatWalk apparatus and can be reproduced with a high degree of fidelity.  
 
4.5.2  Dynamic Gait Parameters Affected by BoNT-A 
Administration of 0.5 ng of BoNT-A at the EPN recovered all impaired dynamic gait 
parameters in lesioned animals within a week of infusion, and these improvements 
persisted for a month post-infusion. Reductions in stand and swing across all limbs are 
linked directly to an overall reduction in step cycle, which suggest that BoNT-A mediated 
effects at the BG contribute to an overall reduction in bradykinesia. Moreover, the 
improvement in step cycle of each limb contributes to the observed increase in average 
speed. Hence, lesioned animals with BoNT-A treatment are once again able to traverse the 
walkway more rapidly because each paw is spending less contact on the glass plate and in 
the air. Additionally, the reduction in body speed variation signifies that the timing of each 
contact and non-contact amongst affected and unaffected paws is remaining more 
consistent after treatment. Thus, it is postulated that the unaffected right paws must be 
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compensating for the affected left paws in order to maintain a straight and steady path down 
the narrow walkway. Furthermore, the increase in swing speed across all limbs, and 
especially in the hind paws, suggests that initiation of movements is facilitated by BoNT-
A administration. In quadrupeds, slower movements of the hindlimbs is more directly 
related to disturbances in balance and thus, amelioration of swing speed in the hindlimbs 
by BoNT-A also likely contributes to the ability of treated animals to maintain a straighter 
path down the walkway (Vlamings et al., 2007). Lastly, the asymmetric impairment in 
terminal dual stance was also significantly improved by BoNT-A, which suggests that 
freezing of gait could be minimized by BoNT-A.  
Thus, overall, hemiparkinsonian animals treated with BoNT-A are able to spontaneously 
walk at a more consistent and rapid pace. These alterations in dynamic gait parameters are 
postulated to reflect a reduction in bradykinesia, facilitation of motor initiation and 
minimization of freezing. Amongst dynamic gait parameters, there is also compensation 
by unaffected paws which contribute to and maintain these improvements.    
 
4.5.3  Static Gait Parameters Unaffected by BoNT-A 
On the contrary, infusion of 0.5 ng of BoNT-A at the EPN failed to ameliorate most 
dysfunctional static gait parameters of 6-OHDA lesioned rodents. The asymmetric 
impairments in max contact area and mean intensity in the left paws persisted following 
BoNT-A administration. Gait disturbances in max contact area and mean intensity are most 
likely associated to an increase in rigidity and an altered use of the paw surface, and thus 
unilateral injection of BoNT-A unsuccessfully reduces asymmetric rigidity and/or relieves 
an imbalanced paw use.  
Interestingly, although 6-OHDA lesioning of the MFB did not significantly impair stride 
length, administration of BoNT-A did significantly increase stride length across all paws. 
In the right paws, this increase was observed as early as 1 week and in the left paws, it 
emerged at 1 month. This change in stride length most likely reflects an altered walking 
pattern and the ability of animals to take larger and further steps to cross the walkway. 
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Thus, as patients with PD present with smaller shuffling steps, it is postulated that BoNT-
A administration could ameliorate a reduced stride length.   
 
4.5.4  BoNT-A versus Other Interventions in 6-OHDA Rodents 
Although this project is the first to investigate the role of BoNT-A at the EPN of 6-OHDA 
lesioned animals with an automated gait analysis tool, other studies have examined the 
effect of other common therapies in parkinsonian rodents with the CatWalk apparatus.  
A study by Westin et al. (2012) reported that administration of a single dose of L-DOPA 
in bilaterally lesioned animals restored most impaired dynamic gait parameters including 
a reduced swing speed, impaired stance and prolonged step cycle. L-DOPA also 
completely restored the impaired stride length of parkinsonian animals. Although authors 
did not directly report on other static gait parameters such as max contact area or mean 
intensity, it was observed that base of support was not affected by L-DOPA. Compared to 
the improvements induced by BoNT-A at the EPN, there are many parallels between the 
beneficial effects of these two interventions. Both clearly predominantly affect dynamic 
gait parameters and have a lesser effect on static gait parameters. Thus, it is likely that 
BoNT-A is exerting its effect by modulating the downstream pathways of the dopaminergic 
system within the BG. Furthermore, supported by the results presented by Westin et al., it 
is well-established that there is a limited role of L-DOPA therapy for axial symptoms in 
PD. However, our project examined more gait parameters, including terminal dual stance 
which best reflects postural instability, and found that BoNT-A improved the asymmetric 
postural instability of unilaterally lesioned animals. Thus, by intervening at the level of the 
EPN and focusing on targeting the glutamatergic system, it is postulated that BoNT-A is 
exerting a role that extends beyond the dopaminergic motor circuit within the BG.   
Similarly, a study by Chuang et al. (2010) investigated the rescuing effect of dopaminergic 
neuron transplantation on gait function of unilaterally 6-OHDA lesioned animals and found 
ameliorations in both dynamic and static gait parameters. Following transplantation of 
dopaminergic neurons derived from embryonic stem cells, 6-OHDA lesioned rodents 
demonstrated improvements in max contact area, mean intensity and base of support, as 
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well as swing speed. It is interesting that the effect of L-DOPA versus dopaminergic neuron 
engraftment lead to benefits in opposing gait parameters. This could be attributed to 
changes in dopamine uptake (L-DOPA) versus release (stem cells) following these 
different interventions and their subsequent effect on the corticostriatal motor circuitry.  
Furthermore, a study by Vlamings et al. (2007) utilized the CatWalk apparatus to examine 
the effect of high frequency stimulation of the subthalamic nucleus on bilaterally 6-OHDA 
lesioned rodents. Bilateral STN electrical stimulation significantly improved overall speed 
of animals (marked only by a reduction in swing duration) but failed to improve static gait 
parameters, including max contact area and mean intensity. In fact, it appeared that STN 
stimulation worsened these static parameters and induced a slowing of forelimb movement 
(i.e. further reduced swing speed). STN stimulation also failed to have any effect on 
hindlimb impairments. As authors did not report directly on individual dynamic gait 
parameters, it is difficult to compare the findings presented in this paper with the results 
observed in our project. However, as hindlimbs in quadrupeds are mainly involved in the 
control of balance and postural stability, the findings by Vlamings et al. provide further 
evidence that electrical stimulation of the STN does not improve deficits in balance and 
postural instability. This is similar to clinical findings in which bilateral STN stimulation 
usually fails to restore postural instability and balance impairments in PD patients 
(Krystkowiak et al., 2003). As our findings suggest that BoNT-A at the EPN does 
ameliorate many hindlimb deficits of parkinsonian animals and dynamic parameters such 
as terminal dual stance, there is a clear potential that this intervention could meet some of 
the shortcomings of DBS. This also indicates that a molecular therapeutic targeting the 
interaction between the STN-EPN offers different consequences than an electrical 
intervention. Thus, although the two interventions focus on the same dysregulated sites in 





4.5.5  Putting It All Together: BG Involvement in Locomotion 
Disorders of the BG network including PD are associated with an inability to initiate 
voluntary movements, an irregularity in the amount and velocity and amount of movement, 
and an abnormal muscle tone (Takakusaki, Tomita, & Yano, 2008). Together these 
contribute to gait failure and locomotor abnormalities. Normal gait is regulated by 
complex, intricate and overlapping loops involving the BG, cerebral cortex and cerebellum. 
The control of voluntary movements and automatic execution of learned movements is 
predominately controlled by BG and intermediate cerebellar loops with motor areas of the 
cerebral cortex, whereas the programming and planning of visually guided movements is 
linked to BG and lateral cerebellar loops with the prefrontal cortex (Marsden, 1982; 
Middleton & Strick, 2000). Additionally, the automaticity and rhythmicity of limb 
movements during locomotion is most widely associated to the connectivity between the 
BG and brainstem. Specifically, the GABAergic BG outputs from the SNpr and the GPi to 
the PPN within the mesencephalic locomotor region (MLR) play a key role in the 
maintenance of muscle tone and the rhythmicity of locomotion (Woolf & Butcher, 1986; 
Inglis & Winn, 1995; Pahapill & Lazano, 2000; Takakusaki et al., 2008). A study by 
Takakusaki et al. (2008) explored the connectivity between the SNpr and PPN/MLR, and 
found that GABAergic antagonists to the PPN altered locomotion in decerebrated cats with 
nigral and/or PPN stimulation. The authors found that dorsolateral SNpr and mid to medial 
SNpr projections to the PPN are required for a basal level of muscle tone. However, this 
study did not examine the specificity and role of the GPi projections to the PPN.  
Combined with the results of our study, in which dynamic aspects of gait were altered by 
BoNT-A injections at the EPN, it is thus postulated that dynamic aspects of locomotion, 
such as speed and velocity could be more heavily influenced by the GPi/EPN output to 
thalamocortical centres. In contrast, the static aspects of gait unaffected by BoNT-A 
injections at the EPN, such as max contact area and mean intensity are linked more closely 
to alterations in muscle tone, and more likely associated to the SNpr output to the brainstem 
via the PPN. Hence, in the parkinsonian state, excessive GABAergic inhibition from the 
GPi/EPN to thalamocortical centres leads to bradykinesia and overall impairment in 
locomotion, which is reflected by reductions in average speed, stance, swing, step cycle 
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and duty cycle. Thus, BoNT-A injections at the EPN lead to recovery of these dynamic 
parameters. Concurrently, increased GABAergic inhibition from the SNpr to the PPN in 
the parkinsonian state consequently results in dysregulation of muscle tone. However, 
BoNT-A injections at the EPN failed to improve impairments in static gait parameters, 




Neuromodulation at the scale of the neuron remains a challenge. Interventions such as 
lesion surgery or brain stimulation offer a limited therapeutic benefit and due to the 
aggressive nature, these treatment options are restricted to a small population that meets 
very specific criteria. There is still a clear unmet need for exploring interventions that offer 
novel neuromodulatory effects, target multiple sites within the brain, be potentially less 
invasive and less restrictive to patients. Central BoNT-A is a safe and viable option 
(Chapter 4.1) for targeted chemical neuromodulation with a well-established mechanism 
of action. Our study directly explored the re-purposing of BoNT-A, an already accepted 
therapeutic agent in PD, in a novel and innovative manner. This is the first study to 
conclude a significant preferential effect by BoNT-A on glutamatergic terminals at the site 
of injection in an animal model (Chapter 4.2). Central administration of 0.5 ng of BoNT-
A has an immediate and transient behavioural effect on apomorphine-induced rotations and 
spontaneous locomotion. Despite a significant dopaminergic lesion, motor and gait 
impairments can be significantly restored by modulation of the BG network with the use 
of BoNT-A (Chapters 4.3 and 4.4). Specifically, the ability of BoNT-A to significantly 
improve impaired dynamic gait parameters offers insight to its potential as a novel 
intervention for PD, as well as the role of the STN-EPN connectivity in locomotion 




4.6.2  Limitations  
Despite the significant findings of this project, there are several limitations which must be 
considered. First, interpretation of data from experimental quadrupedal hemiparkinsonian 
rodents and extrapolation of this data to bipedal PD patients must be taken with careful 
consideration. In general, bipedal human locomotion is less stable than quadrupedal animal 
locomotion and is hypothesized to require additional descending cerebral cortical control 
involving the cerebellum (Takakusaki et al., 2008). As discussed in Chapter 1.3, although 
the unilateral 6-OHDA model of PD was cautiously chosen as the most well-suited animal 
model for this project, there are inherent limitations to this rodent model. The 6-OHDA 
unilateral model allowed for the performance of drug-induced rotational testing, but does 
not reflect the accurate clinical bilateral degeneration of PD patients. Likewise, successful 
6-OHDA lesioning of the MFB lead to a sudden and drastic loss of dopaminergic terminals 
at the striatum (>95%), which does not reflect the true progressive nature of this disease. 
Ultimately, all research involving experimental animals will have associated limitations 
which must be considered, yet they remain vital in the development of novel therapeutics. 
Another limitation of this study was the use of sucrose pellets in the CatWalk testing as it 
places emphasis on reward and motivational behaviour, rather than solely spontaneous 
locomotion. The dopaminergic system is crucially involved in motivation and reward-
seeking behaviour and thus, the loss of dopamine in PD contributes to apathy, 
impulsiveness and other non-motor behavioural impairments (Schultz, 2002; Bromberg-
Martin, Matsumoto, & Hikosaka, 2010). Furthermore, 6-OHDA lesioning of the MFB in 
rodents does not selectively target the nigrostriatal pathway as it also impairs the 
mesolimbic dopaminergic system, therefore affecting reward and motivation (Ma et al., 
2014). Thus, the gait impairments following 6-OHDA lesioning and subsequent 
improvement following BoNT-A treatment may not be solely linked to changes in motor 
pathways within the basal ganglia, but also affected by other dopaminergic pathways.   
A third limitation of this study was the lack of behavioural testing at a 2-month 
experimental timepoint. This oversight was due to an original experimental timeline of a 
year, in which animals were to be tested at 1 week/1 month/3 months/6 months/1 year post-
treatment. This timeline was initially set based on other studies involving behavioural 
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testing of animals injected centrally with BoNT-A. However, as our findings diverged from 
the planned timeline and experimental groups were already underway, the crucial 2-month 
timepoint was missed. Nonetheless, current and future studies in our lab involving central 
BoNT-A injections in experimental animals are and will be performed with the inclusion 
of this timepoint.   
Furthermore, another limitation of this project was the inconclusiveness of the spread of 
BoNT-A by staining either directly for BoNT-A or indirectly for cleaved SNAP-25. 
Commercially available antibodies for BoNT-A (anti-BoNT-A; Meridian Life Science; 
C01372M; Monoclonal; Mouse: 1:50-1:200) and cleaved SNAP-25 (anti-cSNAP25; 
Meridian Life Science; Q01235M; Monoclonal; Mouse: 1:200-1:500) failed to 
demonstrate any specificity for the substrate of interest. In other words, positive immuno-
reactive staining for these markers was detected in both sham and lesioned brains with 
vehicle injection (data not shown). Moreover, there have been many published studies in 
which the antibodies used to detect cleaved SNAP-25 by western blots and 
immunohistochemical assays have been questioned for their reliability and specificity 
(Antonucci et al., 2008; Matak, Riederer, & Lacković, 2012). In 2017, a recent paper by 
Cai et al. (2017) claimed to have developed a highly selective antibody for the cleaved 
substrate of BoNT-A, SNAP25197, but this antibody is proprietary to Allergan plc. Thus, 
there is a need for commercially available antibodies for either cleaved SNAP-25 and/or 
BoNT-A to be developed and validated for immunohistochemical studies.  
Lastly, a final limitation of this study was the lack of consideration for cholinergic inputs 
to the EPN. As the PPN is implicated to play a key role in gait, there is a possibility that 
the behavioural changes induced by BoNT-A injections could be mediated by a reduction 
of cholinergic transmission from the PPN to the EPN (Woolf & Butcher, 1986). Along 
with the analysis of glutamatergic and GABAergic terminals in the EPN, immunostaining 
for cholinergic terminals (i.e. choline acetyltransferase (ChAT) labeling) could be 
performed to identify any potential changes in this pathway.  
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4.6.3  Future Directions 
The findings of this study offered deeper insight into the therapeutic application of BoNT-
A in the CNS to treat neurological disorders including PD. Higher doses and/or repeated 
cycles of injection at the EPN may be promising for a longer and sustained duration of 
improvement. Expansion into other and multiple sites affected in PD, such as the SNpr, 
STN and PPN, could also be beneficial for impairments in specific gait parameters. 
Respective trials in the parkinsonian animal model are currently under way to target other 
hyperactive and dysregulated sites.  
Furthermore, no previous studies have yet examined the effects of BoNT-A in the CNS 
from an electrophysiological perspective. Electrophysiological recordings in BoNT-A 
treated hemiparkinsonian rodents can enhance our current understanding of STN-EPN 
overactivity in PD and its implications in gait and motor control. Simultaneous BoNT-A 
administration and electrophysiological recording by means of injectrodes could also be 
used to compare and understand current data from other therapeutics focusing on the STN, 
such as DBS. This data would provide us with invaluable information in regards to changes 
in firing pattern and connectivity between the cortex and BG.   
Overall, our study offers tremendous potential for a variety of translational studies in the 
future. A similar approach can be used in other rodent models of neurodegenerative 
diseases linked to glutamate excitotoxicity, such as amyotrophic lateral sclerosis and 
Alzheimer’s disease. This study serves as a launching platform for the translation from 
rodents to primates and ultimately, to humans in the future. As BoNT-A is safe, 
commercially available and could be readily paired with established delivery systems, the 
opportunity for delivery of BoNT-A to specific CNS targets is immense. With many 
industry partners currently developing stable room temperature pre-mixed toxins, the path 
to market is rapid and thus, the possibility of delivering BoNT-A chronically in human PD 
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